USRE38425E1 - Semicarbazones having CNS activity and pharmaceutical preparations containing same - Google Patents
Semicarbazones having CNS activity and pharmaceutical preparations containing same Download PDFInfo
- Publication number
- USRE38425E1 USRE38425E1 US09/556,910 US55691000A USRE38425E US RE38425 E1 USRE38425 E1 US RE38425E1 US 55691000 A US55691000 A US 55691000A US RE38425 E USRE38425 E US RE38425E
- Authority
- US
- United States
- Prior art keywords
- hydrogen
- semicarbazone
- benzaldehyde semicarbazone
- compound
- benzaldehyde
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 230000000694 effects Effects 0.000 title description 32
- 150000007659 semicarbazones Chemical class 0.000 title description 10
- 239000000825 pharmaceutical preparation Substances 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 135
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 69
- 239000001257 hydrogen Substances 0.000 claims abstract description 68
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 38
- 206010010904 Convulsion Diseases 0.000 claims abstract description 26
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 26
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 23
- 239000001301 oxygen Substances 0.000 claims abstract description 23
- 241001465754 Metazoa Species 0.000 claims abstract description 21
- -1 C3-9cycloalkyl Chemical group 0.000 claims abstract description 20
- 150000003839 salts Chemical class 0.000 claims abstract description 18
- 125000006545 (C1-C9) alkyl group Chemical group 0.000 claims abstract description 15
- 229910052717 sulfur Chemical group 0.000 claims abstract description 15
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims abstract description 12
- 230000036461 convulsion Effects 0.000 claims abstract description 12
- 239000011593 sulfur Chemical group 0.000 claims abstract description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 11
- 210000003169 central nervous system Anatomy 0.000 claims abstract description 10
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract description 9
- 125000005843 halogen group Chemical group 0.000 claims abstract description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 5
- 241000700159 Rattus Species 0.000 claims description 35
- 238000000034 method Methods 0.000 claims description 34
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 34
- 125000003118 aryl group Chemical group 0.000 claims description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 12
- 230000015572 biosynthetic process Effects 0.000 claims description 12
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 12
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 11
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 8
- 238000004809 thin layer chromatography Methods 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 6
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 6
- 229910052736 halogen Inorganic materials 0.000 claims description 5
- 150000002367 halogens Chemical class 0.000 claims description 5
- ZWDVQMVZZYIAHO-UHFFFAOYSA-N 2-fluorobenzaldehyde Chemical compound FC1=CC=CC=C1C=O ZWDVQMVZZYIAHO-UHFFFAOYSA-N 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 125000004104 aryloxy group Chemical group 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 150000002576 ketones Chemical class 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 4
- 239000002244 precipitate Substances 0.000 claims description 4
- DUIOPKIIICUYRZ-UHFFFAOYSA-N semicarbazide Chemical compound NNC(N)=O DUIOPKIIICUYRZ-UHFFFAOYSA-N 0.000 claims description 4
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical group CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims description 3
- MHUUDVZSPFRUSK-UHFFFAOYSA-N [[4-(4-fluorophenoxy)phenyl]methylideneamino]urea Chemical compound C1=CC(C=NNC(=O)N)=CC=C1OC1=CC=C(F)C=C1 MHUUDVZSPFRUSK-UHFFFAOYSA-N 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 239000007789 gas Substances 0.000 claims description 2
- 230000001590 oxidative effect Effects 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims 27
- 125000001153 fluoro group Chemical group F* 0.000 claims 9
- CPXYGYOMIMOSCX-YRNVUSSQSA-N [(e)-1-phenylethylideneamino]urea Chemical compound NC(=O)N\N=C(/C)C1=CC=CC=C1 CPXYGYOMIMOSCX-YRNVUSSQSA-N 0.000 claims 7
- CIRHAKPWVMBBTB-XFXZXTDPSA-N [(z)-1-phenylpropylideneamino]urea Chemical compound NC(=O)N/N=C(/CC)C1=CC=CC=C1 CIRHAKPWVMBBTB-XFXZXTDPSA-N 0.000 claims 6
- JOMLNPAVOCOQIE-UHFFFAOYSA-N [[4-(4-fluorophenyl)sulfanylphenyl]methylideneamino]urea Chemical compound C1=CC(C=NNC(=O)N)=CC=C1SC1=CC=C(F)C=C1 JOMLNPAVOCOQIE-UHFFFAOYSA-N 0.000 claims 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims 4
- BHPATIXAOIQWHQ-QGMBQPNBSA-N [(e)-[4-(2,4-difluorophenoxy)phenyl]methylideneamino]urea Chemical compound C1=CC(/C=N/NC(=O)N)=CC=C1OC1=CC=C(F)C=C1F BHPATIXAOIQWHQ-QGMBQPNBSA-N 0.000 claims 3
- LMOPONJGKKKIHW-QGMBQPNBSA-N [(e)-[4-(2,5-difluorophenoxy)phenyl]methylideneamino]urea Chemical compound C1=CC(/C=N/NC(=O)N)=CC=C1OC1=CC(F)=CC=C1F LMOPONJGKKKIHW-QGMBQPNBSA-N 0.000 claims 3
- OIHIIODTSOYPTR-QGMBQPNBSA-N [(e)-[4-(2,6-difluorophenoxy)phenyl]methylideneamino]urea Chemical compound C1=CC(/C=N/NC(=O)N)=CC=C1OC1=C(F)C=CC=C1F OIHIIODTSOYPTR-QGMBQPNBSA-N 0.000 claims 3
- FXGVKAGWKGONDY-RQZCQDPDSA-N [(e)-[4-(2-fluorophenoxy)phenyl]methylideneamino]urea Chemical compound C1=CC(/C=N/NC(=O)N)=CC=C1OC1=CC=CC=C1F FXGVKAGWKGONDY-RQZCQDPDSA-N 0.000 claims 3
- RMNIZJBVMFHIGN-QGMBQPNBSA-N [(e)-[4-(3,4-difluorophenoxy)phenyl]methylideneamino]urea Chemical compound C1=CC(/C=N/NC(=O)N)=CC=C1OC1=CC=C(F)C(F)=C1 RMNIZJBVMFHIGN-QGMBQPNBSA-N 0.000 claims 3
- WFKAOJIZWYQQOA-RQZCQDPDSA-N [(e)-[4-(4-bromophenoxy)phenyl]methylideneamino]urea Chemical compound C1=CC(/C=N/NC(=O)N)=CC=C1OC1=CC=C(Br)C=C1 WFKAOJIZWYQQOA-RQZCQDPDSA-N 0.000 claims 3
- LPTHMNSRTDOFIV-LSCVHKIXSA-N [(z)-[4-(2,3-difluorophenoxy)phenyl]methylideneamino]urea Chemical compound C1=CC(\C=N/NC(=O)N)=CC=C1OC1=CC=CC(F)=C1F LPTHMNSRTDOFIV-LSCVHKIXSA-N 0.000 claims 3
- OUVRQJKXNVXDLL-MFOYZWKCSA-N [(z)-[4-(3-fluorophenoxy)phenyl]methylideneamino]urea Chemical compound C1=CC(\C=N/NC(=O)N)=CC=C1OC1=CC=CC(F)=C1 OUVRQJKXNVXDLL-MFOYZWKCSA-N 0.000 claims 3
- NDIGMDVZEBQULC-UHFFFAOYSA-N [[4-(2-bromo-4-fluorophenoxy)phenyl]methylideneamino]urea Chemical compound C1=CC(C=NNC(=O)N)=CC=C1OC1=CC=C(F)C=C1Br NDIGMDVZEBQULC-UHFFFAOYSA-N 0.000 claims 3
- PBMYGBVDLKMNHS-UHFFFAOYSA-N [[4-(2-chloro-4-fluorophenoxy)phenyl]methylideneamino]urea Chemical compound C1=CC(C=NNC(=O)N)=CC=C1OC1=CC=C(F)C=C1Cl PBMYGBVDLKMNHS-UHFFFAOYSA-N 0.000 claims 3
- KITYRHYSAFLDAL-UHFFFAOYSA-N [[4-(4-bromophenyl)sulfanylphenyl]methylideneamino]urea Chemical compound C1=CC(C=NNC(=O)N)=CC=C1SC1=CC=C(Br)C=C1 KITYRHYSAFLDAL-UHFFFAOYSA-N 0.000 claims 3
- VYCHOERZTGRWHO-UHFFFAOYSA-N [[4-(4-chloro-2-fluorophenoxy)phenyl]methylideneamino]urea Chemical compound C1=CC(C=NNC(=O)N)=CC=C1OC1=CC=C(Cl)C=C1F VYCHOERZTGRWHO-UHFFFAOYSA-N 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical compound SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 claims 3
- ZUTQBSQKJGTKCW-LICLKQGHSA-N [(e)-[4-(2-methylphenoxy)phenyl]methylideneamino]urea Chemical compound CC1=CC=CC=C1OC1=CC=C(\C=N\NC(N)=O)C=C1 ZUTQBSQKJGTKCW-LICLKQGHSA-N 0.000 claims 2
- JDSAPELXZAXKBB-QGMBQPNBSA-N [(e)-[4-(3,4-dichlorophenoxy)phenyl]methylideneamino]urea Chemical compound C1=CC(/C=N/NC(=O)N)=CC=C1OC1=CC=C(Cl)C(Cl)=C1 JDSAPELXZAXKBB-QGMBQPNBSA-N 0.000 claims 2
- SKSVDBVQOMQIQU-LICLKQGHSA-N [(e)-[4-(3-methylphenoxy)phenyl]methylideneamino]urea Chemical compound CC1=CC=CC(OC=2C=CC(\C=N\NC(N)=O)=CC=2)=C1 SKSVDBVQOMQIQU-LICLKQGHSA-N 0.000 claims 2
- GVGKJCSRQCWHIH-WOJGMQOQSA-N [(e)-[4-(4-ethylphenoxy)phenyl]methylideneamino]urea Chemical compound C1=CC(CC)=CC=C1OC1=CC=C(\C=N\NC(N)=O)C=C1 GVGKJCSRQCWHIH-WOJGMQOQSA-N 0.000 claims 2
- BINXDPOTJMIGSI-RQZCQDPDSA-N [(e)-[4-(4-iodophenoxy)phenyl]methylideneamino]urea Chemical compound C1=CC(/C=N/NC(=O)N)=CC=C1OC1=CC=C(I)C=C1 BINXDPOTJMIGSI-RQZCQDPDSA-N 0.000 claims 2
- XWCJEYYRESWLGB-UHFFFAOYSA-N [[4-(4-butan-2-ylphenoxy)phenyl]methylideneamino]urea Chemical compound C1=CC(C(C)CC)=CC=C1OC1=CC=C(C=NNC(N)=O)C=C1 XWCJEYYRESWLGB-UHFFFAOYSA-N 0.000 claims 2
- KGCLQYJJYBYXOV-UHFFFAOYSA-N [[4-(4-chlorophenyl)sulfanylphenyl]methylideneamino]urea Chemical compound C1=CC(C=NNC(=O)N)=CC=C1SC1=CC=C(Cl)C=C1 KGCLQYJJYBYXOV-UHFFFAOYSA-N 0.000 claims 2
- IJCJKVOENIBZPH-UHFFFAOYSA-N [[4-(4-cyanophenoxy)phenyl]methylideneamino]urea Chemical compound C1=CC(C=NNC(=O)N)=CC=C1OC1=CC=C(C#N)C=C1 IJCJKVOENIBZPH-UHFFFAOYSA-N 0.000 claims 2
- QKHHNTODWRRCQH-UHFFFAOYSA-N [[4-(4-methylphenyl)sulfanylphenyl]methylideneamino]urea Chemical compound C1=CC(C)=CC=C1SC1=CC=C(C=NNC(N)=O)C=C1 QKHHNTODWRRCQH-UHFFFAOYSA-N 0.000 claims 2
- ACJTZJXCRJAKMZ-UHFFFAOYSA-N [[4-(4-propylphenoxy)phenyl]methylideneamino]urea Chemical compound C1=CC(CCC)=CC=C1OC1=CC=C(C=NNC(N)=O)C=C1 ACJTZJXCRJAKMZ-UHFFFAOYSA-N 0.000 claims 2
- SBZXKBVAQSBMJO-UHFFFAOYSA-N [[4-(4-tert-butylphenoxy)phenyl]methylideneamino]urea Chemical compound C1=CC(C(C)(C)C)=CC=C1OC1=CC=C(C=NNC(N)=O)C=C1 SBZXKBVAQSBMJO-UHFFFAOYSA-N 0.000 claims 2
- QGNYMAULWWKXPN-UHFFFAOYSA-N 4-(4-iodophenoxy)benzaldehyde Chemical compound C1=CC(I)=CC=C1OC1=CC=C(C=O)C=C1 QGNYMAULWWKXPN-UHFFFAOYSA-N 0.000 claims 1
- RDSXMWPLZFRVOT-RQZCQDPDSA-N [(e)-[4-(4-chlorophenoxy)phenyl]methylideneamino]urea Chemical compound C1=CC(/C=N/NC(=O)N)=CC=C1OC1=CC=C(Cl)C=C1 RDSXMWPLZFRVOT-RQZCQDPDSA-N 0.000 claims 1
- MHUUDVZSPFRUSK-RQZCQDPDSA-N [(e)-[4-(4-fluorophenoxy)phenyl]methylideneamino]urea Chemical compound C1=CC(/C=N/NC(=O)N)=CC=C1OC1=CC=C(F)C=C1 MHUUDVZSPFRUSK-RQZCQDPDSA-N 0.000 claims 1
- BWNUULGIXVKMQL-UHFFFAOYSA-N [[2-(4-fluorophenyl)sulfanyl-1-phenylethylidene]amino]urea Chemical compound C=1C=CC=CC=1C(=NNC(=O)N)CSC1=CC=C(F)C=C1 BWNUULGIXVKMQL-UHFFFAOYSA-N 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 238000000935 solvent evaporation Methods 0.000 claims 1
- 238000000638 solvent extraction Methods 0.000 claims 1
- 238000005406 washing Methods 0.000 claims 1
- 239000001961 anticonvulsive agent Substances 0.000 abstract description 14
- 230000001773 anti-convulsant effect Effects 0.000 abstract description 9
- 229960003965 antiepileptics Drugs 0.000 abstract description 9
- 206010029350 Neurotoxicity Diseases 0.000 description 24
- 206010044221 Toxic encephalopathy Diseases 0.000 description 24
- 230000007135 neurotoxicity Effects 0.000 description 24
- 231100000228 neurotoxicity Toxicity 0.000 description 24
- 241000699670 Mus sp. Species 0.000 description 22
- 238000012360 testing method Methods 0.000 description 19
- 0 [1*]C.[2*]C.[3*]C.[4*]C.[5*]/C(=N\NC(N)=O)C1=CC=C(CC2=CC=CC=C2)C=C1 Chemical compound [1*]C.[2*]C.[3*]C.[4*]C.[5*]/C(=N\NC(N)=O)C1=CC=C(CC2=CC=CC=C2)C=C1 0.000 description 15
- 238000011156 evaluation Methods 0.000 description 11
- 239000007928 intraperitoneal injection Substances 0.000 description 11
- 230000002082 anti-convulsion Effects 0.000 description 10
- 238000003786 synthesis reaction Methods 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 8
- 239000000543 intermediate Substances 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- CWRVKFFCRWGWCS-UHFFFAOYSA-N Pentrazole Chemical compound C1CCCCC2=NN=NN21 CWRVKFFCRWGWCS-UHFFFAOYSA-N 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 7
- 229960005152 pentetrazol Drugs 0.000 description 7
- 229960002036 phenytoin Drugs 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 238000007920 subcutaneous administration Methods 0.000 description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 6
- 238000007912 intraperitoneal administration Methods 0.000 description 6
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 6
- QMGVPVSNSZLJIA-FVWCLLPLSA-N strychnine Chemical compound O([C@H]1CC(N([C@H]2[C@H]1[C@H]1C3)C=4C5=CC=CC=4)=O)CC=C1CN1[C@@H]3[C@]25CC1 QMGVPVSNSZLJIA-FVWCLLPLSA-N 0.000 description 6
- 229940102566 valproate Drugs 0.000 description 6
- 206010009346 Clonus Diseases 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- RWWYLEGWBNMMLJ-YSOARWBDSA-N remdesivir Chemical compound NC1=NC=NN2C1=CC=C2[C@]1([C@@H]([C@@H]([C@H](O1)CO[P@](=O)(OC1=CC=CC=C1)N[C@H](C(=O)OCC(CC)CC)C)O)O)C#N RWWYLEGWBNMMLJ-YSOARWBDSA-N 0.000 description 5
- 125000001424 substituent group Chemical group 0.000 description 5
- IYGYMKDQCDOMRE-QRWMCTBCSA-N Bicculine Chemical compound O([C@H]1C2C3=CC=4OCOC=4C=C3CCN2C)C(=O)C2=C1C=CC1=C2OCO1 IYGYMKDQCDOMRE-QRWMCTBCSA-N 0.000 description 4
- LHNKBXRFNPMIBR-UHFFFAOYSA-N Picrotoxin Natural products CC(C)(O)C1(O)C2OC(=O)C1C3(O)C4OC4C5C(=O)OC2C35C LHNKBXRFNPMIBR-UHFFFAOYSA-N 0.000 description 4
- AACMFFIUYXGCOC-UHFFFAOYSA-N bicuculline Natural products CN1CCc2cc3OCOc3cc2C1C4OCc5c6OCOc6ccc45 AACMFFIUYXGCOC-UHFFFAOYSA-N 0.000 description 4
- 229960000623 carbamazepine Drugs 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- IYGYMKDQCDOMRE-UHFFFAOYSA-N d-Bicucullin Natural products CN1CCC2=CC=3OCOC=3C=C2C1C1OC(=O)C2=C1C=CC1=C2OCO1 IYGYMKDQCDOMRE-UHFFFAOYSA-N 0.000 description 4
- VJKUPQSHOVKBCO-AHMKVGDJSA-N picrotoxin Chemical compound O=C([C@@]12O[C@@H]1C[C@]1(O)[C@@]32C)O[C@@H]3[C@H]2[C@@H](C(=C)C)[C@@H]1C(=O)O2.O=C([C@@]12O[C@@H]1C[C@]1(O)[C@@]32C)O[C@@H]3[C@H]2[C@@H](C(C)(O)C)[C@@H]1C(=O)O2 VJKUPQSHOVKBCO-AHMKVGDJSA-N 0.000 description 4
- 230000036515 potency Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- QMGVPVSNSZLJIA-UHFFFAOYSA-N Nux Vomica Natural products C1C2C3C4N(C=5C6=CC=CC=5)C(=O)CC3OCC=C2CN2C1C46CC2 QMGVPVSNSZLJIA-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 241001279009 Strychnos toxifera Species 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 230000000216 proconvulsive effect Effects 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 229960005453 strychnine Drugs 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical class O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 229940125681 anticonvulsant agent Drugs 0.000 description 2
- XEVRDFDBXJMZFG-UHFFFAOYSA-N carbonyl dihydrazine Chemical compound NNC(=O)NN XEVRDFDBXJMZFG-UHFFFAOYSA-N 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical class C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000001037 epileptic effect Effects 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 230000003228 microsomal effect Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- XSXHWVKGUXMUQE-UHFFFAOYSA-N osmium dioxide Inorganic materials O=[Os]=O XSXHWVKGUXMUQE-UHFFFAOYSA-N 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000000384 rearing effect Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- VIJSPAIQWVPKQZ-BLECARSGSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-4-methylpentanoyl]amino]-4,4-dimethylpentanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O VIJSPAIQWVPKQZ-BLECARSGSA-N 0.000 description 1
- VIMMECPCYZXUCI-MIMFYIINSA-N (4s,6r)-6-[(1e)-4,4-bis(4-fluorophenyl)-3-(1-methyltetrazol-5-yl)buta-1,3-dienyl]-4-hydroxyoxan-2-one Chemical compound CN1N=NN=C1C(\C=C\[C@@H]1OC(=O)C[C@@H](O)C1)=C(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 VIMMECPCYZXUCI-MIMFYIINSA-N 0.000 description 1
- AHZCYZMNFBGXAC-UHFFFAOYSA-N 1-[[5-chloro-2-(trifluoromethyl)phenyl]methyl]-7-(2-piperazin-1-ylpyridin-4-yl)-3,4-dihydro-2h-pyrido[2,3-b]pyrazine Chemical compound FC(F)(F)C1=CC=C(Cl)C=C1CN1C2=CC(C=3C=C(N=CC=3)N3CCNCC3)=CN=C2NCC1 AHZCYZMNFBGXAC-UHFFFAOYSA-N 0.000 description 1
- CUDYUNNRMLWYTR-UHFFFAOYSA-N 1-amino-2,2-dimethylcyclopropane-1-carboxylic acid Chemical compound CC1(C)CC1(N)C(O)=O CUDYUNNRMLWYTR-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- OPDGCCBFQWSSCQ-UHFFFAOYSA-N 2-phenoxy-1-phenylpropan-1-one Chemical compound C=1C=CC=CC=1C(=O)C(C)OC1=CC=CC=C1 OPDGCCBFQWSSCQ-UHFFFAOYSA-N 0.000 description 1
- MRLGCTNJRREZHZ-UHFFFAOYSA-N 3-phenoxybenzaldehyde Chemical compound O=CC1=CC=CC(OC=2C=CC=CC=2)=C1 MRLGCTNJRREZHZ-UHFFFAOYSA-N 0.000 description 1
- UOQXIWFBQSVDPP-UHFFFAOYSA-N 4-fluorobenzaldehyde Chemical compound FC1=CC=C(C=O)C=C1 UOQXIWFBQSVDPP-UHFFFAOYSA-N 0.000 description 1
- 108010039931 4-nitroanisole O-demethylase Proteins 0.000 description 1
- QWLHJVDRPZNVBS-UHFFFAOYSA-N 4-phenoxybenzaldehyde Chemical compound C1=CC(C=O)=CC=C1OC1=CC=CC=C1 QWLHJVDRPZNVBS-UHFFFAOYSA-N 0.000 description 1
- UJTTUOLQLCQZEA-UHFFFAOYSA-N 9h-fluoren-9-ylmethyl n-(4-hydroxybutyl)carbamate Chemical compound C1=CC=C2C(COC(=O)NCCCCO)C3=CC=CC=C3C2=C1 UJTTUOLQLCQZEA-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- 102000003849 Cytochrome P450 Human genes 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000016354 Glucuronosyltransferase Human genes 0.000 description 1
- 108010092364 Glucuronosyltransferase Proteins 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000021966 Motor seizure Diseases 0.000 description 1
- 208000002033 Myoclonus Diseases 0.000 description 1
- 102000004960 NAD(P)H dehydrogenase (quinone) Human genes 0.000 description 1
- 108020000284 NAD(P)H dehydrogenase (quinone) Proteins 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- AKQOBHZKBDHWQI-BZEFIUHZSA-N O[C@H]1C[C@@H](CCC1)N1C(C2(C3=C1N=C(N=C3)NC1=CC=C(C=C1)S(=O)(=O)NC([2H])([2H])[2H])CC2)=O Chemical compound O[C@H]1C[C@@H](CCC1)N1C(C2(C3=C1N=C(N=C3)NC1=CC=C(C=C1)S(=O)(=O)NC([2H])([2H])[2H])CC2)=O AKQOBHZKBDHWQI-BZEFIUHZSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 102000004896 Sulfotransferases Human genes 0.000 description 1
- 108090001033 Sulfotransferases Proteins 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- GZGFWFKRWZLNPA-UHFFFAOYSA-N [(4-phenylsulfanylphenyl)methylideneamino]urea Chemical compound C1=CC(C=NNC(=O)N)=CC=C1SC1=CC=CC=C1 GZGFWFKRWZLNPA-UHFFFAOYSA-N 0.000 description 1
- OFLXLNCGODUUOT-UHFFFAOYSA-N acetohydrazide Chemical compound C\C(O)=N\N OFLXLNCGODUUOT-UHFFFAOYSA-N 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- HAMNKKUPIHEESI-UHFFFAOYSA-N aminoguanidine Chemical compound NNC(N)=N HAMNKKUPIHEESI-UHFFFAOYSA-N 0.000 description 1
- 239000008122 artificial sweetener Substances 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- 125000005110 aryl thio group Chemical group 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 description 1
- PASHVRUKOFIRIK-UHFFFAOYSA-L calcium sulfate dihydrate Chemical compound O.O.[Ca+2].[O-]S([O-])(=O)=O PASHVRUKOFIRIK-UHFFFAOYSA-L 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940127108 compound 5g Drugs 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000003269 fluorescent indicator Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 210000003194 forelimb Anatomy 0.000 description 1
- XZBIXDPGRMLSTC-UHFFFAOYSA-N formohydrazide Chemical compound NNC=O XZBIXDPGRMLSTC-UHFFFAOYSA-N 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- BRWIZMBXBAOCCF-UHFFFAOYSA-N hydrazinecarbothioamide Chemical compound NNC(N)=S BRWIZMBXBAOCCF-UHFFFAOYSA-N 0.000 description 1
- 125000000717 hydrazino group Chemical group [H]N([*])N([H])[H] 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 230000007971 neurological deficit Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical class CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 150000003349 semicarbazides Chemical class 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 150000003568 thioethers Chemical group 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 229960000604 valproic acid Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
- C07C281/06—Compounds containing any of the groups, e.g. semicarbazides
- C07C281/08—Compounds containing any of the groups, e.g. semicarbazides the other nitrogen atom being further doubly-bound to a carbon atom, e.g. semicarbazones
- C07C281/14—Compounds containing any of the groups, e.g. semicarbazides the other nitrogen atom being further doubly-bound to a carbon atom, e.g. semicarbazones the carbon atom being further bound to a carbon atom of a six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
- A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
Definitions
- This invention relates to semicarbazone compounds having central nervous system (CNS) activity and to pharmaceutical preparations containing such compounds. More particularly, the invention relates to semicarbazones having anticonvulsant properties and to the use of such semicarbazones for the treatment or prevention of convulsions and seizures in humans and animals.
- CNS central nervous system
- MES maximal electroshock
- scPTZ subcutaneous pentylenetetrazole
- the compounds of formula A displayed neurotoxicity when administered by this route and the protection indices (PI, namely the ratio TD 50 /ED 50 ) of ten representative compounds were low.
- An object of the invention is to provide compounds having central nervous system activity.
- Another object of the invention is to provide pharmaceutical compositions that have good anticonvulsive activity and acceptable neurotoxicity.
- Yet another object of the invention is to provide methods of treating convulsions in humans and animal patients without producing unacceptable side effects.
- R 1 , R 2 , R 3 and R 4 may be the same or different and each represents a hydrogen or halogen atom, or a C 1-9 alkyl, C 5-9 cycloaliphatic, cyano, C 1-9 alkoxy or C 6-10 aryloxy group;
- R 5 represents a hydrogen atom or a C 1-9 alkyl, C 3-9 cycloalkyl or C 6-10 aryl group;
- X is oxygen or sulfur.
- the alkyl substituents, when present, may be straight-chained or branched.
- composition comprising a compound of general formula I and a pharmaceutically acceptable diluent, excipient or carrier.
- a method of treating diseases of the central nervous system of a human or animal patient which comprises administering to said patient an effective amount of a compound of general formula I.
- the compounds of the invention may be administered orally and may exhibit very high potencies against CNS convulsions, e.g. they may possess ED 50 figures (for the maximal electroshock screen in rats) in the 1-5 mg/kg range (more usually the 2-3 mg/kg range) while exhibiting an absence of neurotoxicity at the maximum dose utilized (e.g. 500 mg/kg), thus leading to extremely favourable protection index (PI) values.
- ED 50 figures for the maximal electroshock screen in rats
- the maximum dose utilized e.g. 500 mg/kg
- the compounds of the invention appear to act by one or more mechanisms which are different from those of conventional anticonvulsant drugs. Moreover, the compounds of the invention may be free from some of the disadvantages of conventional anticonvulsant drugs since proconvulsant properties and effects on the activities of certain hepatic enzymes are absent in at least some of the compounds of the invention.
- FIG. 1 is a simplified representation of the postulated receptor site showing different binding regions for the compounds according to the present invention
- FIG. 2 shows basic skeletal structures to indicate the compounds listed in Tables 1 to 3;
- FIG. 3 shows basic chemical structures to indicate the compounds listed in Tables 4 to 6.
- the compounds of the present invention and compounds having related structures can be synthesized by various chemical routes, e.g. by a modification of a method disclosed by Yeager et al. (“A Convenient Method for the Preparation of 4-Aryloxyphenols”, Synthesis, 1991, pp. 63-68; the disclosure of which is incorporated herein by reference).
- Yeager et al. describes a process for producing aryloxybenzaldehydes or aryloxyaryl ketones. These intermediates may then be reacted with semicarbazides. This route is illustrated by the reaction scheme below:
- reaction scheme shown above requires the formation of intermediate aryloxy- or arylthio-benzaldehydes or ketones by reacting appropriate phenols or thiophenols with fluorobenzaldehyde or fluoroaryl ketones in a suitable solvent (e.g. dimethylacetamide) in the presence of anhydrous potassium carbonate at temperatures in the range of 100° to 200° C. under atmospheric pressure of a non-oxidizing gas nitrogen) with reflux for a period of about 5-10 hours. After cooling and water addition, the intermediate compound may be extracted with an organic solvent (e.g. chloroform) and dried.
- a suitable solvent e.g. dimethylacetamide
- the intermediate aryloxy(thio)benzaldehydes aryloxy (thio)aryl ketones are then converted into the desired semicarbazones by reaction with semicarbazide in an aqueous ethanolic solution for a period of one to several hours at ambient temperature, and the resulting precipitate of the final product is then collected and recrystallized.
- the starting materials which are generally reacted in approximately stoichiometrical amounts, are themselves commercially available products and can, in particular, be obtained from the Aldrich Chemical Company, Milwaukee, USA.
- the compounds of the present invention exert their anticonvulsive activity by aligning their molecules at a postulated receptor site in the human or animal brain, and it is theorized that such interactions take place at three areas of the receptor, namely an aryl binding site, a hydrogen bonding area and a distal binding site as illustrated in FIG. 1 .
- compounds of the present invention which are particularly preferred are those in which R 1 and R 2 are hydrogen or halogen (most preferably fluorine), R 3 , R 4 are each hydrogen and R 5 is hydrogen or C 1-3 alkyl, and X is O or S (and most preferably O).
- Particularly preferred compounds according to the present invention are 4-(4′-fluorophenoxy)benzaldehyde semicarbazone and 4-(thiophenoxy)benzaldehyde semicarbazone. These compounds exhibit high activity in the MES screen, low toxicity and afford protection in the corneal kindled rat screen without negative features, such as proconvulsant properties.
- the kindled rat screen is described by R. J. Racine in “Modification of Seizure Activity by Electrical Stimulation. II. Motor Seizure”, Electroencephalogr.Clin.Neurophysiol., 1972, 32, 281-294, and by G. Skeen et al. In “Development of Kindled Seizures Following Electrical Stimulation via the Cornea”, Soc.Neurosci., 1990, 16(1), 307; the disclosures of which are incorporated herein by reference.
- the compounds of the present invention may in some cases have quite high neurotoxicity when injected intraperitoneally in mice. For example, neurotoxicity was found to be present in approximately 65% of the compounds tested and quantitation of the bioactivities of the compounds of the invention has revealed PI's in the range of 2-14 in the MES screen and 1-3 in the scPTZ screen. However, it has been found that such neurotoxicity disappears or is reduced to an acceptable level when the compounds are administered orally to rats. Moreover, while the compounds exhibit high activity in both the MES screen and the scPTZ screen when administered intra-peritoneally, the activity in the MES screen remains high when the compounds are administered orally, but the activity in the scPTZ screen may decline.
- the compounds of the invention may be administered orally to humans, preferably at dosages of 50-75 mg/kg, generally in the form of compositions with inert pharmaceutically-acceptable compounds, for example diluents (e.g. calcium phosphate dihydrate, calcium sulfate dihydrate, cellulose, dextrose, lactose, mannitol, starch, sorbitol, sucrose and sucrose-based materials), binders and adhesives (e.g. acacia, cellulose derivatives, gelatin, glucose, polyvinylpyrrolidone (PVP), alginates, sorbitol, pregelatinized starch or starch paste and tragacanth), disintegrants (e.g.
- diluents e.g. calcium phosphate dihydrate, calcium sulfate dihydrate, cellulose, dextrose, lactose, mannitol, starch, sorbitol, sucrose and sucrose-based materials
- alginates cellulose and cellulose derivatives, clays, cross-linked PVP, starch and starch derivatives
- lubricants e.g. polyethylene glycols, stearic acids, salts and derivatives, surfactants, talc and waxes
- glidants cornstarch, silica derivatives and talc
- colors, flavors and sweeteners e.g. FD&C and D&C dyes and lakes, flavor oils and spray-dried flavors, artificial sweeteners and natural sweeteners.
- compositions may be prepared in any one of the conventional forms for oral administration, e.g. powders, capsules, tablets, caplets, lozenges, solutions, syrups, etc.
- the figures in the table indicate the minimum dose whereby bioactivity was demonstrated in half or more of the mice.
- the animals were examined 0.5 h and 4 h after injections were made.
- the lines indicate an absence of anticonvulsant activity and neurotoxicity.
- the figures in the screen indicate the number of rats out of 4 which were protected.
- the lines mean that no activity was demonstrated and the designation ⁇ indicates that the compound was not screened.
- the 3-phenoxybenzaldehyde used as a starting material required in the synthesis of compounds 3 was obtained from the Aldrich Chemical Company, Milwaukee, Wis.
- the intermediate aryloxyaryl aldehydes required in the synthesis of the other compounds were prepared as follows. Anhydrous potassium carbonate (0.12M) was added to a solution of the appropriate phenol (0.15M) and 4-fluorobenzaldehyde (0.14M) in dimethylacetamide (100 mL). The mixture was heated under reflux at 155° C. under nitrogen and the progress was monitored by thin layer chromatography (TLC) using a solvent system of benzene:methanol (9:1 by volume). After approximately 5-10 hours, the mixture was cooled and water (100 mL) was added.
- TLC thin layer chromatography
- reaction mixture was extracted with chloroform (2 ⁇ 100 mL) and the combined organic extracts were washed with aqueous sodium hydroxide solution (4% w/v) and water. After drying over anhydrous magnesium sulfate, the solvent was removed in vacuo and the resultant oil was distilled under reduced pressure to give the appropriate aryloxyaryl aldehyde. The purity of the distillate was checked by thin layer chromatography (TLC) using benzene:methanol (9:1 by volume) as the solvent.
- TLC thin layer chromatography
- the literature melting point (° C.) of compound 4a was 219°-220° C.
- Example 1 An initial anticonvulsant evaluation of the compounds prepared according to Example 1 was undertaken by administering the compounds by the intraperitoneal route to mice. Protection and/or neurotoxicity was noted 0.5 and 4 hours after administering doses of 30, 100 and 300 mg/kg of each semicarbazone to the animals. These results are presented in Table 1 above.
- livers were removed and comparisons made between the hepatic tissue from treated and control animals, namely liver weights and microsomal protein yields in addition to the enzyme activities of cytochrome P450, p-nitroanisole O-demethylase, UDP-glucuronosyl transferase, sulfotransferase, ethoxyresorfin O-deethylase, pentoxyresorvfin O-dealkylase, glutathione S-transferase and quinone reductase. No differences in the properties between the livers from treated and control livers were detected (p>0.05).
- the ED 50 figures, 95% CI values and slope (SE) for 4b in the MES screen obtained 4h after intraperitoneal injection into rats were as follows: 2.37, 1.39-3.57 and 2.65(0.76) while the corresponding TD 50 data were 80.09,66.14-87.27 and 17.02(6.41).
- the protection afforded after intraperitoneal administration of 125 and 250 mg/kg of 4b in the scPTZ screen was displayed in 0/2 and 1/10 rats.
- the kindled rat test was undertaken by reported procedures (as indicated above). Compound 4b was administered orally and the animals challenged with electrical stimuli 2h later.
- the ED 50 is the dose required to reduce seizures from stage 5 to stage 3 or less and these stages are described as follows namely stage 1 is mouth and facial clonus, stage 2 is stage 1 plus head nodding, stage 3 is stage 2 plus forelimb clonus, stage 4 is stage 3 plus rearing and stage 5 is stage 4 plus repeated rearing and falling.
- the ED 50 (mg/kg), 95% CI and slope (SE) figures for 4b were as follows: 3.93, 2.40-6.09 and 3.62(1.10).
- the ED 50 data (mg/kg, 95% CI in parentheses) and times of the test for three reference drugs were as follows: phenytoin: >100, 0.25 h; carbamazepine: 28.90 (7.72-75.59), 1h and valproate: 117.41 (67.98-189.02), 0.25h.
- Rats were administered 100 mg/kg of 4b daily for 3 days.
- the livers were removed, weighed and the effect of 4b on the liver microsomal system were compared to control animals which received only the vehicle (sonicated 0.5% methylcellulose).
- the semicarbazone 4b afforded no protection in the subcutaneous strychnine test using a dose range of 13.5-108 mg/kg. Two animals per dose were used except in the bicuculline and picrotoxin tests for 4b in which cases, 8 or 16 animals per dose were employed.
- the figures in the table indicate the minimum dose whereby bioactivity was demonstrated in half or more of the mice.
- the animals were examined 0.5 h and 4 h after injections were made.
- the lines indicate an absence of anticonvulsant activity and neurotoxicity.
- the figures in the table indicate the number of rats out of 4 which were protected.
- the lines mean that no activity was demonstrated while the designation ⁇ reveals that the compound was not screened.
- the ED 50 values of the ethers 12a-d were 1.5, 2.5, 1.0 and 2.0 mg/kg respectively and for the thioethers bearing the same aryl substitution pattern namely 16a,15a,16b,c, the figures were 1.5, 2.5, 1.0 and 1.5 mg/kg respectively.
- potencies are unaffected by whether oxygen or sulfur are used as the spacer group.
- the ED 50 values of 12a,15a,16a in the rat oral screen are in the 1-5 mg/kg range whereas for 12a,15a,16b,c the figures in the mouse intraperitoneal test are approximately 15-25 mg/kg.
- the results from the epileptic chicken model are comparable with the data provided in the rat oral screen.
Abstract
A compound of general formula I below useful as an anticonvulsant for disorders of the central nervous system:
wherein: R1, R2, R3 and R4 may be the same or different and each represents a hydrogen or halogen atom, or a C1-9 alkyl, C3-9cycloalkyl, cyano, C1-9alkoxy or C6-10aryloxy group; R5 represents a hydrogen atom or a C1-9alkyl, C3-9cycloalkyl or C6-10aryl group; and X is oxygen or sulfur; or a pharmaceutically-acceptable salt thereof. The compound may be adimistered orally for treating convulsions in humans or animals.
Description
I. Field of the Invention
This invention relates to semicarbazone compounds having central nervous system (CNS) activity and to pharmaceutical preparations containing such compounds. More particularly, the invention relates to semicarbazones having anticonvulsant properties and to the use of such semicarbazones for the treatment or prevention of convulsions and seizures in humans and animals.
II. Description of the Prior Art
There has been a great deal of interest for many years in the identification of drugs that exhibit central nervous system activity in humans and animals and that are, in particular, anticonvulsants used for the treatment or prevention of epileptic seizures and other central nervous system disorders.
A previous study carried out by one of the inventors of the present invention (Dimmock et al., J. Med. Chem., 1993, 36, pp. 2243-2252) revealed that a number of aryl semicarbazones of the general formula A
possess anticonvulsant activity in the maximal electroshock (MES) screen and the subcutaneous pentylenetetrazole (scPTZ) screen when administered by the intraperitoneal route to mice. These screens are test systems developed to detect compounds which will afford protection to generalized tonic-clonic seizures and generalized absence convulsions, respectively. The MES screen and the scPTZ screen have been discussed by Krall, et al. in “Antiepileptic drug development:II. Anticonvulsant drug screening”, Epilepsia, 1978, 19, pp. 409-428; the disclosure of which is incorporated herein by reference.
Nevertheless, the compounds of formula A displayed neurotoxicity when administered by this route and the protection indices (PI, namely the ratio TD50/ED50) of ten representative compounds were low.
There is accordingly a need for compounds showing much improved anticonvulsive effects with reduced toxicity.
An object of the invention is to provide compounds having central nervous system activity.
Another object of the invention is to provide pharmaceutical compositions that have good anticonvulsive activity and acceptable neurotoxicity.
Yet another object of the invention is to provide methods of treating convulsions in humans and animal patients without producing unacceptable side effects.
wherein: R1, R2, R3 and R4 may be the same or different and each represents a hydrogen or halogen atom, or a C1-9alkyl, C5-9cycloaliphatic, cyano, C1-9alkoxy or C6-10aryloxy group; R5 represents a hydrogen atom or a C1-9alkyl, C3-9cycloalkyl or C6-10aryl group; and X is oxygen or sulfur. In the compounds of the invention, the alkyl substituents, when present, may be straight-chained or branched.
It should be noted, however, that the compound of Formula I above in which R1, R2, R3, R4 and R5 are all hydrogen is known from Tomita et. al., “Synthesis of Aldehyde Derivatives Containing a Diphenyl Ether Nucleus”, J. Pharm. Soc. Japan, 1955, 75, 1021-1023, but this reference does not disclose the anticonvulsive property of the compound.
According to another aspect of the invention, there is provided a composition comprising a compound of general formula I and a pharmaceutically acceptable diluent, excipient or carrier.
According to yet another aspect of the invention, there is provided a method of treating diseases of the central nervous system of a human or animal patient, which comprises administering to said patient an effective amount of a compound of general formula I.
The compounds of the invention may be administered orally and may exhibit very high potencies against CNS convulsions, e.g. they may possess ED50 figures (for the maximal electroshock screen in rats) in the 1-5 mg/kg range (more usually the 2-3 mg/kg range) while exhibiting an absence of neurotoxicity at the maximum dose utilized (e.g. 500 mg/kg), thus leading to extremely favourable protection index (PI) values.
The compounds of the invention appear to act by one or more mechanisms which are different from those of conventional anticonvulsant drugs. Moreover, the compounds of the invention may be free from some of the disadvantages of conventional anticonvulsant drugs since proconvulsant properties and effects on the activities of certain hepatic enzymes are absent in at least some of the compounds of the invention.
FIG. 1 is a simplified representation of the postulated receptor site showing different binding regions for the compounds according to the present invention;
FIG. 2 shows basic skeletal structures to indicate the compounds listed in Tables 1 to 3; and
FIG. 3 shows basic chemical structures to indicate the compounds listed in Tables 4 to 6.
The compounds of the present invention and compounds having related structures can be synthesized by various chemical routes, e.g. by a modification of a method disclosed by Yeager et al. (“A Convenient Method for the Preparation of 4-Aryloxyphenols”, Synthesis, 1991, pp. 63-68; the disclosure of which is incorporated herein by reference). Yeager et al. describes a process for producing aryloxybenzaldehydes or aryloxyaryl ketones. These intermediates may then be reacted with semicarbazides. This route is illustrated by the reaction scheme below:
The reaction scheme shown above requires the formation of intermediate aryloxy- or arylthio-benzaldehydes or ketones by reacting appropriate phenols or thiophenols with fluorobenzaldehyde or fluoroaryl ketones in a suitable solvent (e.g. dimethylacetamide) in the presence of anhydrous potassium carbonate at temperatures in the range of 100° to 200° C. under atmospheric pressure of a non-oxidizing gas nitrogen) with reflux for a period of about 5-10 hours. After cooling and water addition, the intermediate compound may be extracted with an organic solvent (e.g. chloroform) and dried. The intermediate aryloxy(thio)benzaldehydes aryloxy (thio)aryl ketones are then converted into the desired semicarbazones by reaction with semicarbazide in an aqueous ethanolic solution for a period of one to several hours at ambient temperature, and the resulting precipitate of the final product is then collected and recrystallized. The starting materials, which are generally reacted in approximately stoichiometrical amounts, are themselves commercially available products and can, in particular, be obtained from the Aldrich Chemical Company, Milwaukee, USA.
Without wishing the invention to be limited to a particular theory, it is believed that the compounds of the present invention exert their anticonvulsive activity by aligning their molecules at a postulated receptor site in the human or animal brain, and it is theorized that such interactions take place at three areas of the receptor, namely an aryl binding site, a hydrogen bonding area and a distal binding site as illustrated in FIG. 1.
These sites are believed to react with the proximal aryl ring (the ring next to the semicarbazono group), the semicarbazono (H2NCONHN═) group itself and the distal aryl ring of the compounds, respectively. The presence of the distal aryl ring and certain substituent groups on the distal and, to a lesser extent, the proximal aryl ring in the compounds of the invention appear to strengthen the attachment of the molecule at the receptor and thus increase the potency of the compounds.
A systematic synthesis and evaluation of compounds of Formula I and compounds with closely related structures has revealed the following general principles
(i) The substitution of the methine hydrogen attached to the carbimino carbon atom by larger groups does not significantly affect the anticonvulsive activity of the compounds; (ii) positioning of the arlyoxy or arylthio group in the ortho or meta positions of the proximal ring leads to a lowering or abolition of anticonvulsive activity; (iii) the substitution of the ether oxygen by sulfur or sulfonyloxy groups leads to compounds with similar anticonvulsive activities, while other spacers lower the anticonvulsive potencies; (iv) a decrease in size of the substituents on the distal aryl ring, increases anticonvulsive activity; and (v) the anticonvulsive activity is high when at least one of the substitutents on the distal alkyl group is in the para position.
Hence, compounds of the present invention which are particularly preferred are those in which R1 and R2 are hydrogen or halogen (most preferably fluorine), R3, R4 are each hydrogen and R5 is hydrogen or C1-3 alkyl, and X is O or S (and most preferably O).
Particularly preferred compounds according to the present invention are 4-(4′-fluorophenoxy)benzaldehyde semicarbazone and 4-(thiophenoxy)benzaldehyde semicarbazone. These compounds exhibit high activity in the MES screen, low toxicity and afford protection in the corneal kindled rat screen without negative features, such as proconvulsant properties. Incidentally, the kindled rat screen is described by R. J. Racine in “Modification of Seizure Activity by Electrical Stimulation. II. Motor Seizure”, Electroencephalogr.Clin.Neurophysiol., 1972, 32, 281-294, and by G. Skeen et al. In “Development of Kindled Seizures Following Electrical Stimulation via the Cornea”, Soc.Neurosci., 1990, 16(1), 307; the disclosures of which are incorporated herein by reference.
The compounds of the present invention may in some cases have quite high neurotoxicity when injected intraperitoneally in mice. For example, neurotoxicity was found to be present in approximately 65% of the compounds tested and quantitation of the bioactivities of the compounds of the invention has revealed PI's in the range of 2-14 in the MES screen and 1-3 in the scPTZ screen. However, it has been found that such neurotoxicity disappears or is reduced to an acceptable level when the compounds are administered orally to rats. Moreover, while the compounds exhibit high activity in both the MES screen and the scPTZ screen when administered intra-peritoneally, the activity in the MES screen remains high when the compounds are administered orally, but the activity in the scPTZ screen may decline. For example, for the compound 4-(4′-fluorophenoxy) benzaldehyde semicarbazone, oral dosing of rats produced an ED50 figure in the rat oral screen of 1.59 mg/kg and a PI of greater than 315. However, the compound did not afford protection in the scPTZ screen at a dose of 125 mg/kg and only 10% of the rats were protected at a dose of 250 mg/kg. An absence of neurotoxicity at the maximum dose utilized (500 mg/kg) led to exceptionally high protection indices.
The compounds of the invention may be administered orally to humans, preferably at dosages of 50-75 mg/kg, generally in the form of compositions with inert pharmaceutically-acceptable compounds, for example diluents (e.g. calcium phosphate dihydrate, calcium sulfate dihydrate, cellulose, dextrose, lactose, mannitol, starch, sorbitol, sucrose and sucrose-based materials), binders and adhesives (e.g. acacia, cellulose derivatives, gelatin, glucose, polyvinylpyrrolidone (PVP), alginates, sorbitol, pregelatinized starch or starch paste and tragacanth), disintegrants (e.g. alginates, cellulose and cellulose derivatives, clays, cross-linked PVP, starch and starch derivatives), lubricants (e.g. polyethylene glycols, stearic acids, salts and derivatives, surfactants, talc and waxes), glidants (cornstarch, silica derivatives and talc), and colors, flavors and sweeteners (e.g. FD&C and D&C dyes and lakes, flavor oils and spray-dried flavors, artificial sweeteners and natural sweeteners).
The compositions may be prepared in any one of the conventional forms for oral administration, e.g. powders, capsules, tablets, caplets, lozenges, solutions, syrups, etc.
The invention is described in more detail in the following Examples, which are nevertheless not intended to limit the scope of the invention.
The compounds 2a to 5v shown in Table 1 below were synthesized by the method previously mentioned. The structures of the listed compounds correspond to those shown in FIG. 2 identified by the same first number (2, 3, 4 or 5), with only the substituents being identified in Table 1.
TABLE 1 |
Aryl Substituents, Physical Data and Anticonvulsant Evaluation after |
Intraperitoneal Injection into Mice and Oral Administration to Rats |
of the Compounds in Series 2-5 |
intraperitoneal injection in micea |
MES | acPTZ | toxicity | oral administration to ratsb | |||||
aryl | yield | screen | screen | screen | dose | MES screen |
compound | substituents | m.p.(° C.) | % | 0.5 h | 4 h | 0.5 h | 4 h | 0.5 h | 4 h | (mg/kg) | 0.25 h | 0.5 h | 1 h | 2 h | 4 h |
2a | H | 198-199 | 40 | — | — | — | — | — | — | 50 | — | — | 2 | 1 | 1 |
2b | 4-F | 210-212 | 48 | — | — | — | — | — | — | 30 | 0 | 0 | 1 | 2 | 4 |
3 | H | 224-225 | 70 | — | 300 | — | — | — | — | 50 | — | — | — | — | — |
4a | H | 224-225 | 60 | 100 | 300 | — | — | — | — | 50 | — | 3 | 4 | 4 | 4 |
4b | 4-F | 233-234 | 65 | 30 | 100 | — | — | — | — | 50 | 2 | 4 | 4 | 4 | 4 |
4c | 4-Cl | 225-226 | 40 | 30 | 30 | 30 | — | 300 | 30 | 50 | 4 | 4 | 4 | 4 | 4 |
4d | 4-Br | 225-226 | 60 | 30 | 30 | — | — | 300 | 30 | 50 | 1 | 4 | 4 | 4 | 4 |
4e | 4-I | 221-222 | 71 | 30 | 30 | 100 | 300 | 300 | 100 | 50 | 3 | 4 | 4 | 4 | 4 |
4f | 4-CH3 | 219-221 | 50 | 30 | 100 | — | — | — | — | 50 | 3 | 4 | 4 | 4 | 4 |
4g | 4-C6H5 | 280 | 72 | — | 300 | — | 300 | — | 300 | 12.5 | — | — | — | 3 | 1 |
4h | 4-OCH3 | 218-220 | 60 | 100 | 100 | — | — | — | 300 | 50 | — | 4 | 4 | 4 | 4 |
4i | 4-OC6H5 | 209-210 | 55 | — | 300 | — | — | — | — | 50 | — | — | — | 1 | 1 |
4j | 4-CN | 218-220 | 40 | 30 | 30 | 30 | 30 | 300 | 100 | 12.5 | 2 | 4 | 4 | 4 | 4 |
5a | 2-F | 228-230 | 42 | 100 | 300 | 300 | — | — | — | 50 | 2 | 4 | 4 | 4 | 4 |
5b | 3-F | 209 | 42 | 30 | 300 | 100 | — | 300 | 300 | 50 | 4 | 4 | 4 | 4 | 4 |
5c | 2,3-F2 | 225 | 50 | 100 | 100 | 300 | — | — | — | 12.5 | - | 3 | 4 | 4 | 4 |
5d | 2,4-F2 | 229-230 | 42 | 30 | 30 | 100 | — | — | — | 50 | 3 | 4 | 4 | 4 | 4 |
5e | 2,5-F2 | 230 | 65 | 100 | 300 | 100 | — | 300 | 300 | 12.5 | — | 1 | 1 | 4 | 1 |
5f | 2,6-F2 | 232 | 30 | 30 | 30 | 300 | 300 | 300 | 300 | 12.5 | 0 | 2 | 4 | 4 | 4 |
5g | 3,4-F2 | 212-213 | 86 | 100 | 30 | 30 | 300 | — | — | 50 | 2 | 4 | 4 | 4 | 4 |
5h | 2-Cl | 207-208 | 42 | 30 | 30 | 100 | 300 | 300 | — | 50 | 3 | 4 | 4 | 4 | 4 |
5i | 3-Cl | 185-186 | 35 | 30 | 100 | 30 | 300 | 300 | 100 | 50 | — | 4 | 4 | 4 | 3 |
5j | 3,4-Cl2 | 216-217 | 45 | 300 | 30 | — | — | — | 300 | 50 | — | 2 | 4 | 4 | 4 |
5k | 2-F, 4-Cl | 225-226 | 60 | 30 | 30 | — | — | 100 | 30 | 12.5 | 2 | 4 | 4 | 4 | 4 |
5l | 2-Cl, 4-F | 209-210 | 59 | 30 | 30 | — | — | 100 | 300 | 50 | 4 | 4 | 4 | 4 | 4 |
5m | 2-Br, 4-F | 203-205 | 40 | 100 | 100 | 300 | — | 300 | 300 | 50 | 4 | 4 | 4 | 4 | 4 |
5n | 2-CH3 | 205 | 25 | 30 | 100 | 100 | 100 | 300 | 300 | 12.5 | — | 4 | 3 | 4 | 4 |
5o | 3-CH3 | 205-206 | 35 | 30 | 100 | — | — | 100 | 300 | 12.5 | — | 4 | 4 | 3 | 2 |
5p | 4-C2H5 | 210 | 40 | 30 | 30 | 300 | — | 300 | 100 | 12.5 | — | 2 | 4 | 4 | 4 |
5q | 4-n-C3H7 | 215 | 53 | 100 | 100 | 300 | — | — | 300 | 12.5 | — | 1 | 2 | 4 | 2 |
5r | 4-n-C4H9 | 192-193 | 38 | 100 | 30 | — | 100 | 300 | 100 | 12.5 | — | 2 | 2 | 3 | 4 |
5s | 4-t-C4H9 | 200-202 | 48 | 100 | 30 | — | 100 | 100 | 100 | 12.5 | — | — | 4 | 4 | 4 |
5t | 4-t-C8H17 | 190 | 30 | — | — | — | — | — | 300 | − | − | − | − | − | − |
5u | 4-O-n-C4H9 | 203 | 35 | 300 | 100 | 300 | 300 | 300 | 300 | 12.5 | — | — | — | — | 2 |
5v | 4-O-n-C7H15 | 204-206 | 20 | — | — | — | — | 300 | − | − | − | − | − | − | − |
Phenytoin | 30 | 30 | — | — | 100 | 100 | − | − | − | − | − | − | ||
Carbamazepine | 30 | 100 | 100 | 300 | 100 | 300 | − | − | − | − | − | − | ||
Valproic acid | — | — | 300 | — | — | — | − | − | − | − | − | − | ||
aDoses of 30, 100 and 300 mg/kg were administered. The figures in the table indicate the minimum dose whereby bioactivity was demonstrated in half or more of the mice. The animals were examined 0.5 h and 4 h after injections were made. The lines — indicate an absence of anticonvulsant activity and neurotoxicity. | ||||||||||||||
bThe figures in the screen indicate the number of rats out of 4 which were protected. The lines — mean that no activity was demonstrated and the designation − indicates that the compound was not screened. |
The details of the syntheses of the various compounds are indicated below.
The 3-phenoxybenzaldehyde used as a starting material required in the synthesis of compounds 3 was obtained from the Aldrich Chemical Company, Milwaukee, Wis. The intermediate aryloxyaryl aldehydes required in the synthesis of the other compounds were prepared as follows. Anhydrous potassium carbonate (0.12M) was added to a solution of the appropriate phenol (0.15M) and 4-fluorobenzaldehyde (0.14M) in dimethylacetamide (100 mL). The mixture was heated under reflux at 155° C. under nitrogen and the progress was monitored by thin layer chromatography (TLC) using a solvent system of benzene:methanol (9:1 by volume). After approximately 5-10 hours, the mixture was cooled and water (100 mL) was added. The reaction mixture was extracted with chloroform (2·100 mL) and the combined organic extracts were washed with aqueous sodium hydroxide solution (4% w/v) and water. After drying over anhydrous magnesium sulfate, the solvent was removed in vacuo and the resultant oil was distilled under reduced pressure to give the appropriate aryloxyaryl aldehyde. The purity of the distillate was checked by thin layer chromatography (TLC) using benzene:methanol (9:1 by volume) as the solvent. The 1H NMR spectrum of a representative intermediate, namely 4-phenoxybenzaldehyde, was as follows: δ(CDCl3):9.94(s,1H, CHO), 7.82-7.88 (2t,2H,ortho H of proximal aryl ring), 7.38-7.46 (3t,2H,meta H of proximal aryl ring), 7.20-7.27(3t,1H,para H of distal aryl ring), 7.03-7.12 (3t,4H, ortho and meta H of distal aryl ring).
A mixture of semicarbazide hydrochloride (0.01M), sodium acetate (0.01M) and water (10 mL) was added slowly to a stirring solution of the aryloxyaryl aldehyde (0.01M) in ethanol (95%, 30 mL). The reaction mixture was stirred at room temperature for 1-2 hours, the precipitate was collected, washed with ether, dried and recrystallized from 95% ethanol (compounds 3, 4b, 4e, 4h, 5b-3, 5k-e, 5v), absolute ethanol (compounds 4a, 4c, 4d, 4g, 4i, 5a, 5fj ,5u) or methanol compound (4f).
The literature melting point (° C.) of compound 4a was 219°-220° C.
The melting points indicated for the various compounds are uncorrected. Elemental analyses (C,H,N) are were within 0.4% of the calculated values except for compound 5n (calcd. for C15H15N3O2:N,15.60. Found: N, 14.80). 1H NMR spectroscopy was undertaken using a BRUKER AM 300 FT (trademark) NMR instrument. Thin layer chromatography (TLC) was performed using silica gel sheets with a fluorescent indicator.
An initial anticonvulsant evaluation of the compounds prepared according to Example 1 was undertaken by administering the compounds by the intraperitoneal route to mice. Protection and/or neurotoxicity was noted 0.5 and 4 hours after administering doses of 30, 100 and 300 mg/kg of each semicarbazone to the animals. These results are presented in Table 1 above.
All of the compounds were active in the MES screen except compounds 2a,b,5t,v and protection was afforded by 60% of the compounds in the scPTZ test. Neurotoxicity was displayed by approximately 70% of the semicarbazones. Bioactivity was quantitated for selected compounds and these data are given in Table 2 below:
TABLE 2 |
Evaluation of Selected Compounds in the MES, acPTZ and Neurotoxicity Screens after |
Intraperitoneal Injection in Mice |
MES screen | acPTZ screen | neurotoxicity screen | PI |
Com- pound | t (h) | ED50 (mg/kg) (95% CI) | slope (SE) | t (h) | ED50 (mg/kg) (95% CI) | slope (SE) | t (h) | TD50(mg/kg) (95% CI) | slope (SE) |
|
|
4b | 1 | 12.86 | 8.28 | 1 | >54 | — | 1 | 108.03 | 3.69 | 8.40 | — |
(10.54- | (3.00) | (71.52- | (0.96) | ||||||||
17.09) | 157.52) | ||||||||||
4f | 1 | 14.65 | 5.59 | 1 | 88.55 | 1.87 | 2 | 203.73 | 4.29 | 13.91 | 2.30 |
(10.44- | (1.91) | (45.52- | (0.57) | (132.44- | (1.31) | ||||||
19.23) | 173.94) | 271.13) | |||||||||
5a | 0.5 | 20.69 | 18.59 | 0.5 | >220 | — | 2 | 170.01 | 12.36 | 8.22 | — |
(18.68- | (5.63) | (146.81- | (3.80) | ||||||||
22.14) | 191.65) | ||||||||||
5c | 1 | 45.78 | 15.53 | 1 | >350 | — | 2 | 292.55 | 5.78 | 6.39 | — |
(41.39- | (5.71) | (209.59- | (1.77) | ||||||||
52.15) | 379.29) | ||||||||||
5d | 0.25 | 11.25 | 2.78 | 0.25 | 57.85 | 1.70 | 1 | 96.81 | 11.50 | 8.61 | 1.67 |
(6.68- | (0.86) | (30.13- | (0.54) | (77.60- | (4.08) | ||||||
19.16) | 93.95) | 113.81) | |||||||||
5g | 1 | 14.48 | 4.62 | 0.5 | 72.78 | 4.27 | 2 | 94.80 | 3.17 | 6.55 | 1.30 |
(9.53- | (1.35) | (49.01- | (1.34) | (59.86- | (1.09) | ||||||
18.91) | 99.12) | 156.29) | |||||||||
5i | 0.5 | 27.69 | 6.01 | 0.5 | 41.16 | 3.53 | 2 | 64.48 | 4.54 | 2.33 | 1.57 |
(20.39- | (2.08) | (26.98- | (0.91) | (42.03- | (1.36) | ||||||
36.12) | 56.74) | 84.72) | |||||||||
5l | 1 | 13.12 | 3.12 | 1 | >68 | — | 1 | 62.46 | 15.48 | 4.76 | — |
(8.70- | (1.03) | (55.56- | (4.84) | ||||||||
20.12) | 67.86) | ||||||||||
5q | scheduled | ||||||||||
5p | scheduled | ||||||||||
5r | 4 | 13.36 | 6.945 | 1 | 86.93 | 11.442 | 4 | 131.27 | 6.467 | 9.825 | 1.510 |
(10.393- | (2.045) | (71.514- | (4.493) | (110.848- | (1.703) | ||||||
16.258 | 108.966) | 158.464) | |||||||||
5s | 4 | 8.87 | 13.063 | 4 | >150.00 | — | 4 | 105.92 | 6.313 | 11.934 | >0.076 |
(7.704- | (3.833) | (85.053- | (1.976) | ||||||||
4.957) | 142.591) | ||||||||||
5t | 2 | 11.27 | 10.881 | 2 | >200 | — | 2 | 124.53 | 3.924 | 11.048 | >0.623 |
(8.313- | (4.272) | (81.064- | (1.095) | ||||||||
12.872) | 175.187) | ||||||||||
Phenytoin | 1 | 6.32 | 11.24 | 1 | >50 | — | 0.5 | 41.23 | 14.39 | 6.52 | — |
(5.44- | (3.52) | (36.90- | (4.82) | ||||||||
7.23) | 46.14) | ||||||||||
Carba- | 0.25 | 9.85 | 20.8 | 0.25 | >50 | — | 0.25 | 47.8 | 7.98 | 4.85 | — |
mazepine | (8.77- | (7.15) | (39.2- | (2.37) | |||||||
10.7) | 59.2) | ||||||||||
Valproate | 0.25 | 287 | 7.31 | 0.25 | 209 | 8.51 | 0.25 | 483 | 12.3 | 1.68 | 2.31 |
(237- | (2.48) | (176- | (2.69) | (412- | (4.01) | ||||||
359) | 249) | 571) | |||||||||
The majority of the compounds were examined for oral activity in rats. Initially doses of 50 mg/kg of the semicarbazones were administered. However as the data in Table 1 reveal, with the exception of compound 3, all compounds examined at this dose displayed activity in the MES screen. In an attempt to discern those compounds possessing marked oral activity, the dose was reduced fourfold to 12.5 mg/kg, revealing that protection in the MES screen was retained in all cases. Using the doses indicated in Table 1, neurotoxicity was absent during the 0.25-4 hour time period with the exception of compound 51 in which case ¼ rats caused neurological deficit 1,2 and 4 hours after oral administration. Compounds 4e,5b,d,g-i,n,g,r were evaluated in the scPTZ screen at the doses indicated in Table 1 but they were either inactive (compounds 5b,d,g,i,g) or displayed only marginal activity, details of which are given below. Quantitation of selected compounds was undertaken and the figures obtained are presented in Table 3.
TABLE 3 |
Evaluation of Selected Compounds in the MES and |
Neurotoxicity Tests after Oral Administration to Rats |
MES screen | neurotoxicity screen |
ED50(mg/kg) | slope | TD50(mg/kg) | slope | ||||
Compound | t (h) | (95% CI) | (SE) | t (h) | (95% CI) | (SE) | PTa |
4b | 2 | 1.59 | 3.17 | ¼-24b | >500 | — | >315 |
(1.01-2.25) | (0.84) | ||||||
4f | 2 | 3.43 | 4.121 | 2 | >500 | >145.57 | |
(2.282-4.726) | (1.324) | ||||||
5c | 4 | 6.15 | 2.55 | — | — | — | — |
(3.69-9.71) | (0.69) | ||||||
5e | 2 | 11.44 | 4.12 | — | — | — | — |
(7.61-15.75) | (1.32) | ||||||
5g | 4 | 2.37 | 3.18 | ¼-24b | >500 | — | >210 |
(1.54-3.62) | (0.81) | ||||||
5k | 4 | 1.13 | 2.661 | >90 | >79.179 | ||
(0.713-2.005) | (0.949) | ||||||
5n | 2 | 5.65 | 3.65 | ¼-24b | >500 | — | >88 |
(3.79-7.81) | (0.98) | ||||||
5o | 1 | 3.07 | 7.114 | >500 | >162.47 | ||
(2.579-3.944) | (2.292) | ||||||
5p | 6 | 6.48 | 1.98 | — | — | — | — |
(2.970-15.536) | (0.753) | ||||||
5q | 2 | 2.63 | 3.213 | >500 | >190.02 | ||
(1.689-3.926) | (0.819) | ||||||
5r | 4 | 3.21 | 3.575 | >3.22 | >100.16 | ||
(2.252-4.636) | (1.022) | ||||||
5s | 4 | 1.68 | 4.437 | >500 | >297.24 | ||
(1.146-2.438) | (1.281) | ||||||
5u | 4 | 45.81 | 1.327 | ||||
(19.481-315.522) | (0.524) | ||||||
Phenytoin | 2 | 23.2 | 15.1 | ¼-24b | >500 | >21.6 | |
(21.4-25.4) | (4.28) | ||||||
Carba- | 1 | 3.57 | 3.84 | 1 | 361 | 11.4 | 101 |
mazepine | (2.41-4.72) | (1.15) | (319-402) | (2.96) | |||
Valproate | 0.5 | 395 | 8.13 | 0.5 | 859 | 6.57 | 2.17 |
(332-441) | (2.76) | (719-1148) | (2.17) | ||||
aPI indicates the protection index i.e. TD50/ED50. | |||||||
bThe compound was examined 0.25, 0.5, 1, 3, 4, 6, 8, and 24 h after administration. |
Further bioevaluations of compound 4b were undertaken. After intraperitoneal injection into rats, the ED50 and TD50 figures in the MES and neurotoxicity screens for 4b were 2.37 and 80.09 mg/kg respectively revealing a PI of 33.8. Using a kindled rat screen, the ED50 figure of this compound was 3.93 mg/kg. A daily dose of 100 mg/kg of 4b was administered orally for three days to rats. Afterwards, the livers were removed and comparisons made between the hepatic tissue from treated and control animals, namely liver weights and microsomal protein yields in addition to the enzyme activities of cytochrome P450, p-nitroanisole O-demethylase, UDP-glucuronosyl transferase, sulfotransferase, ethoxyresorfin O-deethylase, pentoxyresorvfin O-dealkylase, glutathione S-transferase and quinone reductase. No differences in the properties between the livers from treated and control livers were detected (p>0.05).
Both 4b and 5g were examined for proconvulsant properties in the intravenous pentylenetetrazole test in mice; the doses administered were the MES ED50 and the TD50 figures of 4b and 5g indicated in Table 2. Neither compound possessed this undesirable feature and using a dose of 108 mg/kg, 4b increased the time to clonus. Compounds 4b and 5g were also evaluated for their ability to prevent convulsions induced by the subcutaneous administration of bicuculline and picrotoxin in mice. The semicarbazone 4b gave partial protection in these two screens whereas 5g was inactive. In addition 4b afforded no protection in the subcutaneous strychnine test in mice.
Full details of these tests are provided below.
In addition to the information summarized in Table 1, intraperitoneal injection of a number of compounds into mice elicited the following side effects at various doses (mg/kg) and time intervals. First, in the scPTZ screen, myoclonic jerks were noted with the following compounds namely 4c:30,100;0.5h and 5f: 100,300;0.5h. Second continuous seizure activity was observed in the scPTZ screen as follows: 4c:300;0.5h; 100,300;4h; 4d:100,300;0.5 and 4h;4i:100,300;0.5 and 4h;5i:300;0.5h; 51:300,0.5 and 4h;5o:100,300;0.5h and 5s:300;4h. At the end of the 4 hours, continuous seizure activity followed by death resulted in the scPTZ screen when mice received 300 mg/kg of 5o.
Using the doses indicated in Table 1, several compounds showed marginal activity in the scPTZ screen. These compounds as well as the number of rats protected at different time periods are as follows: 4e.:1/4 after 0.5,1,4h; 5h:1/4 after 4h; 5n:1/4 after 0.5,1,2h and 5r: 1/4 after 1,4h and 2/4 after 2 hours.
The ED50 figures, 95% CI values and slope (SE) for 4b in the MES screen obtained 4h after intraperitoneal injection into rats were as follows: 2.37, 1.39-3.57 and 2.65(0.76) while the corresponding TD50 data were 80.09,66.14-87.27 and 17.02(6.41). The protection afforded after intraperitoneal administration of 125 and 250 mg/kg of 4b in the scPTZ screen was displayed in 0/2 and 1/10 rats.
The kindled rat test was undertaken by reported procedures (as indicated above). Compound 4b was administered orally and the animals challenged with electrical stimuli 2h later. The ED50 is the dose required to reduce seizures from stage 5 to stage 3 or less and these stages are described as follows namely stage 1 is mouth and facial clonus, stage 2 is stage 1 plus head nodding, stage 3 is stage 2 plus forelimb clonus, stage 4 is stage 3 plus rearing and stage 5 is stage 4 plus repeated rearing and falling. The ED50 (mg/kg), 95% CI and slope (SE) figures for 4b were as follows: 3.93, 2.40-6.09 and 3.62(1.10). The ED50 data (mg/kg, 95% CI in parentheses) and times of the test for three reference drugs were as follows: phenytoin: >100, 0.25 h; carbamazepine: 28.90 (7.72-75.59), 1h and valproate: 117.41 (67.98-189.02), 0.25h.
Rats were administered 100 mg/kg of 4b daily for 3 days. The livers were removed, weighed and the effect of 4b on the liver microsomal system were compared to control animals which received only the vehicle (sonicated 0.5% methylcellulose).21-23
Compounds 4b and 5g in methylcellulose solution (0.5%) were injected intraperitoneally into mice. The two doses used were the approximate ED50 values in the MES test and the TD50 figures. After 1h, a solution of pentylenetetrazole (0.5%), sodium chloride and sodium heparin (10 USP units/mL) in water were infused into the tail veins of mice at a rate of 0.37 mL/min (4b) and 0.34 mL/min (5g). The times from the commencement-of the infusion until the appearances of the first twitch and also the onset of clonus were recorded for the test and control animals. From these data, the quantities of pentylenetetrazole infused was obtained. Ten animals were used as controls and for each dose administered except for the 13 mg/kg dose of 4b in which case 9 animals were employed. The figures for the times of the first twitch in seconds, quantity of pentylenetetrazole administered in mg/kg (SE) and p values were as follows: 4b(dose of 13 mg/kg): 32.2,32.3(1.4), >0.05;4b(dose of 108 mg/kg):32.2, 32.6(0.8), >0.05; 5g(dose of 15 mg/kg): 32.8,32.9(1.4), >0.05;5g(dose of 95 mg/kg): 34.6,34.6(1.5), >0.05. The relevant data for the times to clonus in seconds, quantity of pentylenetetrazole administered in mg/kg (SE) and p values were as follows: 4b(dose of 13 mg/kg): 37.6, 37.6(1.5), >0.05;4b(dose of 108 mg/kg): 41.5,42.1(1.4), <0.01;5g(15 mg/kg): 41.2,41.2(2.6), 0.05;5g(dose of 95 mg/kg): 44.4, 44.4(2.5), >0.05.
Various doses of 4b and 5g were administered to mice 1h (4b) or 0.5 h (5g) before chemoconvulsant doses of bicuculline and picrotoxin were given subcutaneously to mice. Compound 4b was also examined for protective effects after subcutaneous administration of strychnine. In the case of 4b, the number of animals protected in the subcutaneous bicuculline test at different doses (mg/kg) were as follows: 0/8(54), 3/8(108) and 3/8(216). In the subcutaneous picrotoxin test, the protection at various doses (mg/kg) were as follows: 1/8(27), 5/16(108), 2/8(216). Compound 5g showed no effect in the 12-96 mg/kg dose range in these two tests. The semicarbazone 4b afforded no protection in the subcutaneous strychnine test using a dose range of 13.5-108 mg/kg. Two animals per dose were used except in the bicuculline and picrotoxin tests for 4b in which cases, 8 or 16 animals per dose were employed.
The compounds having the structures shown in Table 4 were prepared. The structures of the listed compounds correspond to those shown in FIG. 3 identified by the same first number (12, 13, 14, 15, 16, 17 or 18), with only the substituents being identified in Table 4.
TABLE 4 |
Aryl Substituents, Physical Data and Anticonvulsant Evaluation after |
Intraperitoneal Injection into Mice and Oral Administration to Rats |
of the Compounds in Series 12-18a |
intraperitoneal injection in miceb |
MES | acPTZ | toxicity | oral administration to ratsc | ||||
m.p. | yield | screen | screen | screen | dose | MES screen |
compound | R1 | R2 | (° C.) | % | 0.5 h | 4 h | 0.5 h | 4 h | 0.5 h | 4 h | (mg/kg) | 0.25 h | 0.5 h | 1 h | 2 h | 4 h |
12a | H | F | 240a | 65 | 30 | 100 | — | — | — | — | 50 | 2 | 4 | 4 | 4 | 4 |
12b | H | H | 224-225 | 60 | 100 | 300 | — | — | — | — | 50 | — | 3 | 4 | 4 | 4 |
12c | H | Cl | 225-226 | 40 | 30 | 30 | 30 | — | 300 | 30 | 50 | 4 | 4 | 4 | 4 | 4 |
12d | H | Br | 225-226 | 60 | 30 | 30 | — | — | 300 | 30 | 50 | 1 | 4 | 4 | 4 | 4 |
12e | H | CH3 | 219-221 | 50 | 30 | 100 | — | — | — | — | 50 | 3 | 4 | 4 | 4 | 4 |
13a | CH3 | H | 169-171 | 60 | 30 | 100 | — | — | 100 | 100 | 30 | 4 | 4 | 4 | 4 | 4 |
13b | CH3 | F | 182-184 | 74 | 30 | 30 | 100 | — | 300 | 100 | 12.5 | — | 4 | 4 | 4 | 4 |
13c | CH3 | Cl | 192-194 | 60 | 30 | 30 | — | 30 | 30 | 100 | 30 | 3 | 4 | 4 | 4 | 4 |
13d | CH3 | Br | 195-197 | 30 | 30 | 30 | 300 | — | 300 | 100 | 12.5 | 1 | 3 | 4 | 4 | 4 |
13e | C2H5 | H | 154-156 | 58 | 30 | 100 | — | — | 100 | 100 | 30 | 1 | 4 | 3 | 3 | — |
13f | C2H5 | F | 170-172 | 72 | 30 | 30 | 100 | — | 300 | 100 | 12.5 | — | 2 | 4 | 4 | 4 |
13g | C2H5 | Cl | 186-188 | 38 | 30 | — | 300 | — | 300 | 100 | 30 | — | 1 | 4 | 4 | 4 |
13h | C2H5 | Br | 184-186 | 38 | 30 | 30 | 100 | — | 300 | 100 | 12.5 | — | 2 | 4 | 4 | 4 |
14a | CH3 | H | 136-138 | 14 | 300 | — | 300 | — | 300 | — | − | − | − | − | − | − |
14b | CH3 | F | 154-157 | 27 | — | — | — | — | — | — | 30 | 1 | 1 | 3 | 3 | 2 |
14c | CH3 | Cl | 167-169 | 32 | 300 | 300 | 300 | 300 | 300 | 300 | − | − | − | − | − | − |
14d | CH3 | Br | 183-186 | 28 | — | — | — | — | 300 | — | − | − | − | − | − | − |
14e | C2H5 | F | 156-158 | 55 | — | — | — | — | — | 300 | 12.5 | — | — | — | — | — |
14f | C2H5 | Cl | 136-138 | 15 | 300 | 300 | — | — | — | — | − | − | − | − | − | − |
14g | C2H5 | Br | 155-157 | 5 | — | — | — | — | — | 300 | − | − | − | − | − | − |
15a | S | H | 226-227 | 40 | 30 | 30 | — | — | — | 300 | 50 | — | 4 | 4 | 4 | 4 |
15b | OCO | H | 237-238 | 70 | — | 300 | — | — | — | — | 12.5 | — | — | — | — | — |
15c | OCO | Cl | 245-246 | 80 | — | 300 | — | — | — | — | 12.5 | 1 | — | 1 | — | 2 |
15d | OCH2 | H | 212-213 | 52 | 300 | 300 | — | 100 | — | — | 12.5 | — | — | 1 | 1 | — |
15e | SO2 | H | 254 | 40 | — | 300 | — | — | — | — | − | − | − | − | − | − |
15f | OSO2 | H | 146 | 40 | 30 | 30 | 30 | — | 300 | 300 | 12.5 | 1 | 2 | 2 | 4 | 3 |
15g | OSO2 | CH3 | 205-207 | 70 | — | — | — | — | — | — | — | — | — | — | — | — |
16a | H | F | 230-231 | 52 | 30 | 30 | 30 | — | 300 | 100 | 12.5 | 1 | 3 | 4 | 4 | 4 |
16b | H | Cl | 216 | 40 | 100 | 30 | 300 | — | — | 100 | 50 | 1 | 4 | 4 | 4 | 4 |
16c | H | Br | 212-213 | 30 | 100 | 30 | — | 300 | — | 300 | 12.5 | 0 | 1 | 3 | 4 | 4 |
16d | H | CH3 | 225-227 | 32 | 30 | 30 | 100 | 100 | 300 | 100 | 12.5 | 0 | 0 | 4 | 4 | 4 |
16e | CH3 | H | 208-210 | 60 | 100 | 100 | 300 | — | — | — | 30 | 0 | 4 | 4 | 4 | 4 |
16f | CH3 | F | 204-207 | 91 | 100 | 30 | — | 300 | 300 | 300 | 30 | 3 | 4 | 4 | 4 | 4 |
16g | C2H5 | H | 131-133 | 16 | 30 | 30 | 100 | 100 | 100 | 100 | 30 | — | 3 | 4 | 3 | 4 |
16h | C2H5 | F | 150-157 | 18 | 30 | 100 | — | — | 100 | 100 | 30 | 0 | 0 | 2 | 3 | 3 |
17a | S | O | 167 | 56 | 30 | 30 | 30 | 30 | 100 | 30 | 12.5 | — | 2 | 2 | 3 | 1 |
17b | NH | O | 181-183 | 50 | 300 | 30 | 30 | — | 100 | 100 | 12.5 | — | — | — | 1 | 2 |
17c | S | S | 171-172 | 62 | 100 | 100 | 100 | 100 | — | 100 | 12.5 | — | 1 | 2 | 1 | 1 |
17d | NH | S | 172-173 | 40 | 300 | — | 30 | 30 | 100 | 100 | 12.5 | — | — | — | 1 | — |
18a | H | O | 176-178 | 60 | 300 | 300 | — | 300 | — | 300 | − | − | − | − | − | − |
18b | CH3 | O | 160 | 83 | 30 | 30 | 100 | 100 | 100 | 100 | 12.5 | 1 | 4 | 2 | 2 | 1 |
18c | NHNH2 | O | 220 | 80 | 300 | 100 | — | 300 | — | 300 | 30 | — | — | — | — | — |
18d | CONH2 | O | 253 | 75 | — | — | — | — | 300 | 300 | — | — | — | — | — | — |
18e | H | S | 146-148 | 80 | 100 | 100 | — | 300 | — | 300 | 30 | 1 | — | — | — | 1 |
Phenytoin | − | − | 30 | 30 | — | — | 100 | 100 | − | − | − | − | − | − | ||
Carbamazepine | − | − | 30 | 100 | 100 | 300 | 100 | 300 | − | − | − | − | − | − | ||
Valproate | − | − | — | — | 300 | — | — | — | − | − | − | − | − | − | ||
aDoses of 30, 100 and 300 mg/kg were administered. The figures in the table indicate the minimum dose whereby bioactivity was demonstrated in half or more of the mice. The animals were examined 0.5 h and 4 h after injections were made. The lines — indicate an absence of anticonvulsant activity and neurotoxicity. | ||||||||||||||||
bThe figures in the table indicate the number of rats out of 4 which were protected. The lines — mean that no activity was demonstrated while the designation − reveals that the compound was not screened. |
These compounds were synthesized as follows, although attempts to isolate 2-phenoxypropiophenone, required in the synthesis of compound 4 (R1═C2H5;R2═H), were unsuccessful; the reactions invariably leading to the formation of a number of compounds. The intermediate aldehydes and ketones were reacted with semicarbazide (13-16), thiosemicarbazide (17a,c), aminoguanidine (17b,d), formic acid hydrazide (18a,e), acetic hydrazide (18b), carbohydrazide (18c) or oxamic hydrazide (18d).
Initial anticonvulsant evaluation of compounds 13-18 was undertaken as follows. Doses of 30, 100 and 300 mg/kg were injected by the intraperitoneal route into mice and evaluated in the MES, scPTZ and neurotoxicity screens one half and four hours after administration. The results are presented in Table 4 above in addition to the data for 12a-e which is included for comparative purposes.
Quantitation of the activity of selected compounds was undertaken and these results are indicated in Table 5.
TABLE 5 |
Quantitation of the Activity of Certain Compounds in the MES, acPTZ and Neurotoxicity |
Screens after Intraperitoneal Injection in Mice |
MES screen | acPTZ screen | neurotoxicity screen |
t | ED50(mg/kg) | slope | t | ED50(mg/kg) | slope | t | TD50(mg/kg) | slope | PI* |
Compound | (h) | (95% CI) | (SE) | (h) | (95% CI) | (SE) | (h) | (95% CI) | (SE) | MES | acPTZ |
12a | 1 | 12.86 | 8.28 | 1 | >54 | — | 1 | 108.03 | 3.69 | 8.40 | — |
(10.54-17.09) | (3.00) | — | — | (71.52-157.52) | (0.96) | ||||||
13a | 0.25 | 9.08 | 6.21 | 0.25 | 43.31 | 1.54 | 1 | 73.48 | 10.51 | 8.09 | 1.70 |
(6.45-11.31) | (1.91) | (18.36-112.07) | (0.57) | (64.32-86.40) | (3.08) | ||||||
13b | 1 | 11.63 | 22.69 | 0.25 | >80 | — | 2 | 60.74 | 45.21 | 5.22 | — |
(10.96-12.48) | (9.34) | — | — | (58.92-63.84) | (14.45) | ||||||
13f | 1 | 5.46 | 11.64 | 2 | 12.84 | 3.34 | 2 | 35.26 | 6.78 | 6.45 | 2.75 |
(4.57-6.46) | (3.74) | (8.25-18.55) | (1.16) | (25.02-43.44) | (2.05) | ||||||
13g | 4 | 11.09 | 20.278 | <100 | <9.017 | ||||||
(10.367-12.583) | (6.827) | ||||||||||
15a | 1 | 15.62 | 4.50 | 1 | >46 | — | 2 | 181.00 | 4.59 | 11.59 | — |
(10.45-20.56) | (1.36) | — | — | (122.53-250.73) | (1.27) | ||||||
15f | 0.5 | 25.27 | 9.52 | 0.5 | >100 | — | 1 | 113.00 | 17.38 | 4.47 | — |
(2.150-29.87) | (3.00) | — | — | (103.0-122.68) | (5.73) | ||||||
16a | 1 | 12.37 | 6.372 | 1 | >120 | 2 | 88.00 | 24.001 | 7.112 | <0.733 | |
(9.247-16.128) | (1.915) | (83.311—94.847) | (6.853) | ||||||||
16b | 1 | 16.22 | 23.21 | 1 | >120 | — | 2 | 53.18 | 5.90 | 3.28 | — |
(14.63-17.59) | (8.59) | — | — | (41.42-72.54) | (1.89) | ||||||
16c | 2 | 24.37 | 5.92 | 2 | >200 | — | 2 | 122.57 | 6.92 | 5.03 | — |
(18.45-30.93) | (1.72) | — | — | (101.63-149.51) | (2.10) | ||||||
16d | 1 | 9.46 | 3.676 | 1 | >300 | 4 | 196.52 | 12.821 | 20.776 | <0.655 | |
(6.353-13.026) | (0.986) | (174.429-226.477) | (3.957) | ||||||||
Phenytoin | 2 | 6.48 | 12.4 | 2 | >50 | — | 0.5 | 42.8 | 10.2 | 6.60 | — |
(5.66-7.24) | (3.60) | — | — | (36.4-47.5) | (3.13) | ||||||
Carbam- | 0.25 | 9.85 | 20.8 | 0.25 | >50 | — | 0.25 | 47.8 | 7.98 | 4.85 | — |
azepine | (8.77-10.7) | (7.15) | — | — | (39.2-59.2) | (2.37) | |||||
Valproate | 0.25 | 287 | 7.31 | 0.25 | 209 | 8.51 | 0.25 | 483 | 12.3 | 1.68 | 2.31 |
(237-359) | (2.48) | (176-249) | (2.69) | (412-571) | (4.01) | ||||||
*The protection index (PI) is obtained by dividing the TD50 figues by the ED50 values. |
Evaluation of most of the semicarbazones and analogs in the MES and neurotoxicity tests after oral administration to rats was performed. At the doses indicated in Table 4, neurotoxicity was absent and some of the compounds examined in the scPTZ screen were either inactive or afforded only minimal protection. Hence only the MES data are presented in Table 4. The ED50 figures of several compounds in the rat oral MES screen are given in Table 6.
TABLE 6 |
Quantitation of the Activity of Selected Compounds |
in the MES and Neurotoxicity Screens after Oral |
Administration to Rats |
MES Screen | Neurotoxicity screen |
ED50(mg/kg) | slope | TD50(mg/kg) | slope | ||||
Compound | t (h) | (95% CI) | (SE) | t(h) | (95% CI) | (SE) | PIa |
12a b | 2 | 1.59 | 3.17 | ¼-24c | >500 | — | >315 |
(1.01-2.25) | (0.84) | — | — | ||||
13a | 4 | 9.73 | 3.844 | — | — | — | — |
(6.440-14.141) | (1.300) | ||||||
13b | 2 | 3.37 | 5.74 | 2 | 108.77 | 4.82 | 32.3 |
(2.37-4.72) | (1.80) | (80.26-177.74) | (1.82) | ||||
13c | 4 | 2.92 | 5.774 | 4 | <500 | — | <170.73 |
(2.203-3.464) | (1.595) | ||||||
13d | 4 | 1.52 | 3.600 | — | >500 | >328.28 | |
(0.989-2.300) | (1.024) | ||||||
13e | 0.5 | 23.08 | 3.14 | — | — | — | — |
(14.33-36.64) | (0.92) | — | — | ||||
13f | 2 | 4.25 | 3.67 | 4 | >72(<240) | −>16.9 | (<56.436) |
(2.89-5.97) | (1.04) | — | — | ||||
13g | 2 | 2.89 | 2.035 | 0 | >500 | — | >172.81 |
(1.568-5.294) | (0.594) | ||||||
13h | 4 | 4.39 | 4.206 | ||||
(2.67-5.833) | (1.279) | ||||||
14b | 2 | 43.37 | 2.287 | ||||
(25.078-66.343) | (0.569) | ||||||
15a | 4 | 4.29 | 6.02 | ¼-24 | >496 | — | >115.6 |
(3.20-5.24) | (2.00) | — | — | ||||
16a | 2 | 4.98 | 3.92 | 4 | 183.05 | 2.49 | 36.8 |
(3.24-7.01) | (1.10) | (100.59-338.35) | (0.86) | ||||
16f | 2 | 9.11 | 5.285 | — | — | — | — |
(6.185-11.658) | (1.496) | ||||||
16g | 2 | 18.58 | 5.238 | — | — | — | — |
(14.195-25.038) | (1.674) | ||||||
18b | 0.5 | 18.66 | 3.93 | 2 | >125 | — | >6.70 |
(12.40-27.60) | (1.11) | — | — | — | |||
Phenytoin | 2 | 23.2 | 15.1 | ¼-24c | >500 | — | >21.6 |
(21.4-25.4) | (4.28) | — | — | ||||
Carbamazepine | 1 | 3.57 | 3.84 | 1 | 361 | 11.4 | 101 |
(2.41-4.72) | (1.15) | (319-402) | (2.96) | ||||
Valproate | 0.5 | 395 | 8.13 | 0.5 | 859 | 6.57 | 2.17 |
(332-441) | (2.76) | (719-1148) | (2.17) | ||||
aThe letters PI refer to the protection index viz TD50/ED50. | |||||||
bData for this compound were taken from |
|||||||
cThe compound was examined 0.25, 0.5, 1, 2, 4, 6, 8 and 24 h after administration. |
The final pharmacological evaluation of representative compounds was undertaken using an epileptic chicken model.6 In this case, the convulsions which are induced by intermittent photic stimulations have been shown to be prevented by a number of anticonvulsants at blood levels similar to those used in humans. Two series of compounds were examined with the aim of observing whether oxygen or sulfur is a preferable spacer atom between the two aryl rings and also to compare the ED50 figures with those obtained in the rat oral and mouse intraperitoneal screens. The ED50 values of the ethers 12a-d were 1.5, 2.5, 1.0 and 2.0 mg/kg respectively and for the thioethers bearing the same aryl substitution pattern namely 16a,15a,16b,c, the figures were 1.5, 2.5, 1.0 and 1.5 mg/kg respectively. Hence potencies are unaffected by whether oxygen or sulfur are used as the spacer group. The ED50 values of 12a,15a,16a in the rat oral screen are in the 1-5 mg/kg range whereas for 12a,15a,16b,c the figures in the mouse intraperitoneal test are approximately 15-25 mg/kg. Hence the results from the epileptic chicken model are comparable with the data provided in the rat oral screen.
Claims (48)
wherein R1, R2, R3 and R4 may be the same or different and each represents hydrogen, halo, C1-9alkyl, C3-9cycloalkyl, cyano, C1-9alkoxy or C6-10aryloxy; R5 represents hydrogen, C1-9alkyl, C3-9cycloalkyl or C6-10aryl; and X is oxygen or sulfur; with the proviso that:
a) if X is sulfur, then at least one of R1 and R2 is other than hydrogen or at least one of R3 and R4 is fluoro, C1-9alkyl, C3-9cycloalkyl, cyano, C1-9alkoxy or C6-10aryloxy; and
b) if X is oxygen, R5 is hydrogen, methyl, or ethyl, and if one of R1 and R2 is chloro or methoxy or if one of R3 and R4 is methyl, then the other of R1 and R2 or the other of R3 and R4 is other than hydrogen; and
c) if X is oxygen, R5 is hydrogen, methyl or ethyl, and if R1 and R2 are both hydrogen, then at least one of R3 and R4 is other than hydrogen and methyl;
or a pharmaceutically acceptable salt thereof.
2. A compound according to claim 1 wherein at least one of R1 and R2 represents fluoro, R3 and R4 are each hydrogen, R5 is hydrogen or C1-3alkyl, and X is O.
3. A compound according to claim 1 wherein at least one of R1 and R2 represent fluoro, R5 is hydrogen, and X represents oxygen.
4. 4-(4′-Fluorophenoxy)benzaldehyde semicarbazone or a pharmaceutically-acceptable salt thereof.
wherein: R1, R2, R3 and R4 may be the same or different and each represents a hydrogen or halogen atom, or a C1-9alkyl, C3-9cycloalkyl, cyano, C1-9alkoxy or C6-10aryloxy group; R5 represents a hydrogen atom or a C1-9alkyl, C3-9cycloalkyl or C6-10aryl group; and X is oxygen or sulfur; except that R1, R2, R3, R4 and R5 may not all be hydrogen; with the provisos that:
(a) if X is sulfur, then at least one of R 1 and R 2 is other than hydrogen or at least one of R 3 and R 4 is fluoro, C 1-9 alkyl, C 3-9 cycloalkyl, cyano, C 1-9 alkoxy or C 6-10 aryloxy; and
(b) if X is oxygen, and R 5 is hydrogen, methyl, or ethyl, and one of R 1 and R 2 is chloro, then (i) the other of R 1 and R 2 is other than hydrogen or chloro, or (ii) at least one of R 3 and R 4 is other than hydrogen; and
(c) if X is oxygen, and R 5 is hydrogen, methyl, or ethyl, and one of R 1 and R 2 is methoxy, then (i) the other of R 1 and R 2 is other than hydrogen or methoxy, or (ii) at least one of R 3 and R 4 is other than hydrogen; and
(d) if X is oxygen, and R 5 is hydrogen, methyl, or ethyl, and one of R 1 and R 2 is methyl, then (i) the other of R 1 and R 2 is other than hydrogen or (ii) at least one of R 3 and R 4 is other than hydrogen; and
(e) if X is oxygen, R 5 is hydrogen, methyl or ethyl, and R 1 and R 2 are both hydrogen, then at least one of R 3 and R 4 is other than hydrogen and methyl;
which method comprises forming an intermediate aryloxy- or arylthio-benzaldehydes or ketones by reacting a corresponding (thio)phenol with fluorobenzaldehyde or a fluoroaryl ketone in a solvent in the presence of potassium carbonate at temperatures in the range of 100° to 200° C. under a non-oxidizing gas, extracting the intermediate and then reacting the intermediate with semicarbazide and collecting the resulting precipitate of the desired compound.
6. A method of treating a human or animal patient for a disorder of the central nervous system, comprising administering to said patient an effective amount of a compound having the general formula I:
wherein: R1, R2, R3 and R4 may be the same or different and each represents hydrogen, halo, C1-9alkyl, C3-9cycloalkyl, cyano, C1-9alkoxy or C6-10aryloxy; R5 represents hydrogen, C1-9alkyl, C3-9cycloalkyl or C6-10aryl; and X is oxygen or sulfur; with the proviso that; :
a) at least one of R1, R2, R3 or R4 is other than hydrogen, or
b) R5 is other than hydrogen, methyl and ethyl;
or a pharmaceutically acceptable salt thereof.
7. A method according to claim 6 wherein said disorder exhibits convulsions or seizures.
8. A method according to claim 6 wherein said disorder exhibits epileptic seizures.
9. A compound of claim 1 which is selected from the group consisting of 4-(4-bromophenoxy)benzaldehyde semicarbazone; 4-(4-iodophenoxy)benzaldehyde semicarbazone; 4-(4-methylphenoxy)benzaldehyde semicarbazone; 4-(4-cyanophenoxy)benzaldehyde semicarbazone; 4-(2-fluorophenoxy)benzaldehyde semicarbazone; 4-(3-fluorophenoxy)benzaldehyde semicarbazone; 4-(2,3-difluorophenoxy)benzaldehyde semicarbazone; 4-(2,4-difluorophenoxy)benzaldehyde semicarbazone; 4-(2,5-difluorophenoxy)benzaldehyde semicarbazone; 4-(2,6-difluorophenoxy)benzaldehyde semicarbazone; 4-(3,4-difluorophenoxy)benzaldehyde semicarbazone; 4-(3,4-dichlorophenoxy)benzaldehyde semicarbazone; 4-(4-chloro-2-fluorophenoxy)benzaldehyde semicarbazone; 4-(2-chloro-4-fluorophenoxy)benzaldehyde semicarbazone; 4-(2-bromo-4-fluorophenoxy)benzaldehyde semicarbazone; 4-(2-methylphenoxy)benzaldehyde semicarbazone; 4-(3-methylphenoxy)benzaldehyde semicarbazone; 4-(4-ethylphenoxy)benzaldehyde semicarbazone; 4-(4-n-propylphenoxy)benzaldehyde semicarbazone; 4-(4-s-butylphenoxy)benzaldehyde semicarbazone; 4-(4-t-butylphenoxy)benzaldehyde semicarbazone; 4-(4-fluorophenoxy)acetophenone semicarbazone; 4-(4-bromophenoxy)acetophenone semicarbazone; 4-(4-fluorophenoxy)propiophenone semicarbazone; 4-(4-bromophenoxy)propiophenone semicarbazone; 4-(4-fluorophenylmercapto)benzaldehyde semicarbazone; 4-(4-chlorophenylmercapto)benzaldehyde semicarbazone; 4-(4bromophenylmercapto)benzaldehyde semicarbazone; 4-(4-methylphenylmercapto)benzaldehyde semicarbazone; and 4(4-fluorophenylmercapto)acetophenone semicarbazone.
10. A composition comprising the compound of any one of claims 1-4 and 9, and a pharmaceutically acceptable diluent, excipient or carrier.
11. A method of treating a human or animal patient for a disorder of the central nervous system comprising administering to said patient an effective amount of a compound of any one of claims 1-4 and 9, or a pharmaceutically acceptable salt thereof.
12. A method according to claim 11 , wherein said disorder exhibits convulsions or seizures.
13. A method according to claim 12 , wherein said disorder exhibits epileptic seizures.
14. A method according to claim 6 , wherein said compound is administered as part of a composition comprising a pharmaceutically acceptable carrier.
15. A method according to claim 11 , wherein said compound is administered as part of a composition comprising a pharmaceutically acceptable carrier.
16. A method according to claim 6 , wherein X is oxygen.
17. A method according to claim 6 , wherein one of R1 and R 2 is halogen, and the other of R 1 and R 2 is hydrogen or halogen, R 3 and R 4 are each hydrogen, R 5 is hydrogen or C 1-3 alkyl, and X is O or S.
18. A method according to claim 17 , wherein at least one of R1 and R 2 is fluoro.
19. A method according to claim 17 , wherein X is O.
20. A method according to claim 6 , wherein said compound possesses an ED50 from 1 to 5 mg/kg in a maximal electroshock screen in rate.
21. The method according to claim 20 , wherein said compound possesses an ED50 from 2 to 3 mg/kg in a maximal electroshock screen in rats.
or a pharmaceutically acceptable salt thereof, wherein:
R
1
and R
2
are independently hydrogen or halogen;
R
3
and R
4
are each hydrogen;
R
5
is hydrogen or C
1-3
alkyl; and
X is O or S;
provided that R
1
and R
2
are not both hydrogen, R
1
and R
2
do not consist of hydrogen and chloro, and R
1
and R
2
are not both chloro.
23. A compound according to claim 22 , wherein X is O.
24. A compound according to claim 22 , wherein at least one of R1 and R 2 is fluoro.
25. A compound according to claim 22 , wherein R5 is hydrogen.
26. A compound selected from the group consisting of:
4 -( 4 -bromophenoxy)benzaldehyde semicarbazone; and
4 -( 4 -iodophenoxy)benzaldehyde semicarbozone;
or a pharmaceutically acceptable salt thereof.
27. A compound selected from the group consisting of:
4 -( 2 -fluorophenoxy)benzaldehyde semicarbazone;
4 -( 3 -fluorophenoxy)benzaldehyde semicarbazone;
4 -( 2,3 -difluorophenoxy)benzaldehyde semicarbazone;
4 -( 2,4 -difluorophenoxy)benzaldehyde semicarbazone;
4 -( 2,5 -difluorophenoxy)benzaldehyde semicarbazone;
4 -( 2,6 -difluorophenoxy)benzaldehyde semicarbazone; and
4 -( 3,4 -difluorophenoxy)benzaldehyde semicarbazone;
or a pharmaceutically acceptable salt thereof.
28. A compound selected from the group consisting of:
4 -( 4 -chloro- 2 -fluorophenoxy)benzaldehyde semicarbazone;
4 -( 2 -chloro- 4 -fluorophenoxy)benzaldehyde semicarbazone; and
4 -( 2 -bromo- 4 -fluorophenoxy)benzaldehyde semicarbazone;
or a pharmaceutically acceptable salt thereof.
29. A compound selected from the group consisting of:
4 -( 4 -fluorophenoxy)acetophenone semicarbazone;
4 -( 4 -bromophenoxy)acetophenone semicarbazone;
4 -( 4 -fluorophenoxy)propiophenone semicarbazone;
4 -( 4 -bromophenoxy)propiophenone semicarbazone;
4 -( 4 -fluorophenylmercapto)benzaldehyde semicarbazone;
4 -( 4 -bromophenylmercapto)benzaldehyde semicarbazone; and
4 -( 4 -fluorophenylmercapto)acetophenone semicarbazone;
or a pharmaceutically acceptable salt thereof.
31. The compound 4-( 4 -chlorophenoxy)benzaldehyde semicarbazone or a pharmaceutically-acceptable salt thereof.
or a pharmaceutically acceptable salt thereof, wherein
R
1
, R
2
, R
3
and R
4
may be the same or different and each represents hydrogen, halo, C
1-9
alkyl, C
3-9
cycloalkyl, cyano, C
1-9
alkoxy or C
6-10
aryloxy;
R
5
represents hydrogen, C
1-9
alkyl, C
3-9
cycloalkyl or C
6-10
aryl; and
X is oxygen or sulfur;
with the provisos that:
(a) if X is sulfur, then at least one of R 1 and R 2 is other than hydrogen or at least one of R 3 and R 4 is fluoro, C 1-9 alkyl, C 3-9 cycloalkyl, cyano, C 1-9 alkoxy or C 6-10 aryloxy; and
(b) if X is oxygen, and R 5 is hydrogen, methyl, or ethyl, and one of R 1 and R 2 is chloro, then (i) the other of R 1 and R 2 is other than hydrogen or chloro, or (ii) at least one of R 3 and R 4 is other than hydrogen; and
(c) if X is oxygen, and R 5 is hydrogen, methyl, or ethyl, and one of R 1 and R 2 is methoxy, then (i) the other of R 1 and R 2 is other than hydrogen or methoxy, or (ii) at least one of R 3 and R 4 is other than hydrogen; and
(d) if X is oxygen, and R 5 is hydrogen, methyl, or ethyl, and one of R 1 and R 2 is methyl, then (i) the other of R 1 and R 2 is other than hydrogen or (ii) at least one of R 3 and R 4 is other than hydrogen; and
(e) if X is oxygen, R 5 is hydrogen, methyl or ethyl, and R 1 and R 2 are both hydrogen, then at least one of R 3 and R 4 is other than hydrogen and methyl.
33. A compound according to claim 32 , wherein at least one of R1 and R 2 represents fluoro, R 3 and R 4 are each hydrogen, R 5 is hydrogen or C 1-3 alkyl, and X is oxygen.
34. A compound according to claim 32 , wherein at least one of R1 and R 2 represent fluoro, R 5 is hydrogen, and X represents oxygen.
35. 4-( 4 -Fluorophenoxy)benzaldehyde semicarbazone or a pharmaceutically acceptable salt thereof.
36. The compound of claim 32 , wherein said compound is selected from the group consisting of:
4 -( 4 -bromophenoxy)benzaldehyde semicarbazone;
4 -( 4 -iodophenoxy)benzaldehyde semicarbazone;
4 -( 4 -cyanophenoxy)benzaldehyde semicarbazone;
4 -( 2 -fluorophenoxy)benzaldehyde semicarbazone;
4 -( 3 -fluorophenoxy)benzaldehyde semicarbazone;
4 -( 2,3 -difluorophenoxy)benzaldehyde semicarbazone;
4 -( 2,4 -difluorophenoxy)benzaldehyde semicarbazone;
4 -( 2,5 -difluorophenoxy)benzaldehyde semicarbazone;
4 -( 2,6 -difluorophenoxy)benzaldehyde semicarbazone;
4 -( 3,4 -difluorophenoxy)benzaldehyde semicarbazone;
4 -( 4 -chloro- 2 -fluorophenoxy)benzaldehyde semicarbazone;
4 -( 2 -chloro- 4 -fluorophenoxy)benzaldehyde semicarbazone;
4 -( 2 -bromo- 4 -fluorophenoxy)benzaldehyde semicarbazone;
4 -( 4 -ethylphenoxy)benzaldehyde semicarbazone;
4 -( 4 -n-propylphenoxy)benzaldehyde semicarbazone;
4 -( 4 -s-butylphenoxy)benzaldehyde semicarbazone;
4 -( 4 -t-butylphenoxy)benzaldehyde semicarbazone;
4 -( 4 -fluorophenoxy)acetophenone semicarbazone;
4 -( 4 -bromophenoxy)acetophenone semicarbazone;
4 -( 4 -fluorophenoxy)propiophenone semicarbazone;
4 -( 4 -bromophenoxy)propiophenone semicarbazone;
4 -( 4 -fluorophenylmercapto)benzaldehyde semicarbazone;
4 -( 4 -chlorophenylmercapto)benzaldehyde semicarbazone;
4 -( 4 -bromophenylmercapto)benzaldehyde semicarbazone;
4 -( 4 -methylphenylmercapto)benzaldehyde semicarbazone; and
4 -( 4 -fluorophenylmercapto)benzaldehyde semicarbazone.
37. 4-( 3,4 -Dichlorophenoxy)benzaldehyde semicarbazone or a pharmaceutically acceptable salt thereof.
38. A compound selected from the group consisting of:
4 -( 2 -methylphenoxy)benzaldehyde semicarbazone;
4 -( 3 -methylphenoxy)benzaldehyde semicarbazone; and
4 -( 4 -methylphenoxy)benzaldehyde semicarbazone;
or a pharmaceutically acceptable salt thereof.
39. A composition comprising the compound of any one of claims 32-38 and a pharmaceutically acceptable diluent, excipient or carrier.
40. A method of treating a human or animal patient for a disorder of the central nervous system comprising administering to said patient an effective amount of a compound of any one of claims 32-38, or a pharmaceutically acceptable salt thereof.
41. A method according to claim 40 , wherein said disorder exhibits convulsions or seizures.
42. A method according to claim 41 , wherein said disorder exhibits epileptic seizures.
43. A method according to claim 40 , wherein said compound is administered as part of a composition comprising a pharmaceutically acceptable carrier.
44. The method of claim 5 , wherein said method comprises:
(i) forming an intermediate aryloxy- or arylthio-benzaldehyde or ketone by reacting a corresponding (thio)phenol with fluorobenzaldehyde or a fluoroaryl ketone in a solvent in the presence of potassium carbonate at temperatures in the range of 100° to 200° C. under nitrogen;
(ii) monitoring for formation of said intermediate by thin layer chromatography;
(iii) adding water to the solvent containing said intermediate;
(iv) partitioning the intermediate into chloroform to form an intermediate solution;
(v) washing the intermediate solution with dilute aqueous sodium hydroxide;
(vi) drying the washed intermediate solution over anhydrous magnesium sulfate;
(vii) removing the chloroform from the dried and washed intermediate solution by solvent evaporation under vacuum to form an oil;
(viii) distilling said oil under reduced pressure to provide an extracted intermediate;
(ix) reacting the extracted intermediate with semicarbazide; and
(x) collecting the resulting precipitate of the desired compound.
45. The method of claim 44 , wherein at (i) said solvent is dimethylacetamide.
46. The method of claim 44 , wherein at (i) said temperature is about 155° C.
47. The method of claim 44 , wherein at (i) the molar ratio of said corresponding (thio)phenol and said fluorobenzaldehyde or fluoroaryl ketone is 0.15:0.14.
48. The method of claim 44 , wherein at (v) said dilute aqueous sodium hydroxide is about 4 % sodium hydroxide and about 96 % water (weight/volume).
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/556,910 USRE38425E1 (en) | 1995-06-07 | 2000-04-20 | Semicarbazones having CNS activity and pharmaceutical preparations containing same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/475,313 US5741818A (en) | 1995-06-07 | 1995-06-07 | Semicarbazones having CNS activity and pharmaceutical preparations containing same |
US09/556,910 USRE38425E1 (en) | 1995-06-07 | 2000-04-20 | Semicarbazones having CNS activity and pharmaceutical preparations containing same |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/475,313 Reissue US5741818A (en) | 1995-06-07 | 1995-06-07 | Semicarbazones having CNS activity and pharmaceutical preparations containing same |
Publications (1)
Publication Number | Publication Date |
---|---|
USRE38425E1 true USRE38425E1 (en) | 2004-02-10 |
Family
ID=23887035
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/475,313 Ceased US5741818A (en) | 1995-06-07 | 1995-06-07 | Semicarbazones having CNS activity and pharmaceutical preparations containing same |
US09/556,910 Expired - Fee Related USRE38425E1 (en) | 1995-06-07 | 2000-04-20 | Semicarbazones having CNS activity and pharmaceutical preparations containing same |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/475,313 Ceased US5741818A (en) | 1995-06-07 | 1995-06-07 | Semicarbazones having CNS activity and pharmaceutical preparations containing same |
Country Status (24)
Country | Link |
---|---|
US (2) | US5741818A (en) |
EP (1) | EP0836591B1 (en) |
JP (1) | JPH11506109A (en) |
KR (1) | KR19990022408A (en) |
CN (1) | CN1062263C (en) |
AT (1) | ATE206110T1 (en) |
AU (1) | AU715897B2 (en) |
BR (1) | BR9609408A (en) |
CA (1) | CA2223935A1 (en) |
CZ (1) | CZ387497A3 (en) |
DE (1) | DE69615558T2 (en) |
DK (1) | DK0836591T3 (en) |
ES (1) | ES2164889T3 (en) |
FI (1) | FI974447A0 (en) |
GE (1) | GEP20012414B (en) |
HU (1) | HUP9802637A3 (en) |
IL (1) | IL122350A0 (en) |
NO (1) | NO310655B1 (en) |
NZ (1) | NZ309707A (en) |
PL (1) | PL184048B1 (en) |
PT (1) | PT836591E (en) |
RU (1) | RU2174115C2 (en) |
UA (1) | UA62915C2 (en) |
WO (1) | WO1996040628A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7074813B2 (en) | 2001-05-10 | 2006-07-11 | Cytovia, Inc. | Substituted N′-(arylcarbonyl)-benzhydrazides, N′-(arylcarbonyl)-benzylidene-hydrazides and analogs as activators of caspases and inducers of apoptosis and the use thereof |
US20090186893A1 (en) * | 2007-06-08 | 2009-07-23 | Mannkind Corporation | IRE-1alpha INHIBITORS |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5741818A (en) | 1995-06-07 | 1998-04-21 | University Of Saskatchewan | Semicarbazones having CNS activity and pharmaceutical preparations containing same |
WO1998047869A1 (en) | 1997-04-22 | 1998-10-29 | Cocensys, Inc. | Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof |
EP1568690A1 (en) * | 1997-04-22 | 2005-08-31 | Euro-Celtique S.A. | The use of carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones as sodium channel blockers |
EP2201944B1 (en) | 1997-11-21 | 2012-05-23 | Purdue Neuroscience Company | Use of substituted 2-aminoacetamides for treating, preventing or ameliorating manic depression |
GB9727523D0 (en) | 1997-12-31 | 1998-02-25 | Pharmacia & Upjohn Spa | Alpha-aminoamide derivatives useful as analgesic agents |
MXPA00007585A (en) * | 1998-02-04 | 2002-10-17 | Euro Celtique Sa | Substituted semicarbazides and the use thereof. |
US6281211B1 (en) | 1999-02-04 | 2001-08-28 | Euro-Celtique S.A. | Substituted semicarbazides and the use thereof |
BR0009322A (en) | 1999-03-26 | 2002-04-30 | Euro Celtique Sa | Pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles replaced with aryl and their use |
EP1169060B1 (en) * | 1999-04-09 | 2005-08-31 | Euro-Celtique S.A. | Sodium channel blocker compositions and the use thereof |
MXPA02006079A (en) | 1999-12-20 | 2004-08-23 | Nicholas J Kerkhof | Process for producing nanometer particles by fluid bed spraydrying. |
US8771740B2 (en) | 1999-12-20 | 2014-07-08 | Nicholas J. Kerkhof | Process for producing nanoparticles by spray drying |
AR029489A1 (en) | 2000-03-10 | 2003-07-02 | Euro Celtique Sa | PIRIDINES, PYRIMIDINES, PIRAZINAS, TRIAZINES REPLACED BY ARILO, PHARMACEUTICAL COMPOSITIONS AND THE USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT |
PL214230B1 (en) * | 2000-03-24 | 2013-07-31 | Euro Celtique Sa | Aryl substituted pyrazoles, triazoles and tetrazoles, and the use thereof |
GB0025208D0 (en) | 2000-10-13 | 2000-11-29 | Euro Celtique Sa | Delayed release pharmaceutical formulations |
EP1399159A4 (en) * | 2001-06-01 | 2007-02-14 | Cytovia Inc | 4-substituted-1-(arylmethylidene)thiosemicarbazide, 4-substituted-1-(arylcarbonyl)thiosemicarbazide and analogs as activators of caspases and inducers of apoptosis and the use thereof |
WO2003006426A1 (en) * | 2001-07-13 | 2003-01-23 | Axxima Pharmaceuticals Ag | Aromatic guanylhydrazones as effective compounds against neurodiseases |
EP1423168B1 (en) * | 2001-09-03 | 2006-02-08 | Newron Pharmaceuticals S.p.A. | Pharmaceutical composition comprising gabapentin or an analogue thereof and an alpha-aminoamide and its analgesic use |
AR037233A1 (en) | 2001-09-07 | 2004-11-03 | Euro Celtique Sa | PIRIDINAS ARIL REPLACED, PHARMACEUTICAL COMPOSITIONS AND THE USE OF SUCH COMPOUNDS FOR THE PREPARATION OF A MEDICINAL PRODUCT |
AR036873A1 (en) | 2001-09-07 | 2004-10-13 | Euro Celtique Sa | PIRIDINAS ARIL REPLACED A, PHARMACEUTICAL COMPOSITIONS AND THE USE OF THE SAME FOR THE PREPARATION OF A MEDICINAL PRODUCT |
US7528164B2 (en) * | 2002-05-16 | 2009-05-05 | Cytovia, Inc. | Substituted 4-aryl-4h-pyrrolo[2,3-h]chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof |
WO2003096982A2 (en) * | 2002-05-16 | 2003-11-27 | Cytovia, Inc. | Substituted 4h-chromenes, 2h-chromenes, chromans and analogs as activators of caspases and inducers of apoptosis and the use thereof |
EP1438956A1 (en) * | 2003-01-16 | 2004-07-21 | Newron Pharmaceuticals S.p.A. | Alpha-aminoamide derivatives useful as antimigraine agents |
AU2005282028B2 (en) * | 2004-09-10 | 2011-03-24 | Newron Pharmaceuticals S.P.A. | (halobenzyloxy) benzylamino-propanamides as sodium and/or calcium channel selective modulators |
WO2010068804A1 (en) * | 2008-12-10 | 2010-06-17 | Boston Scientific Scimed, Inc. | Method of forming a joint between a titanium alloy member and a steel alloy member and medical device comprising said joint |
CN104402771B (en) * | 2014-11-26 | 2016-09-28 | 玉林师范学院 | The synthesis of hydroxy benzaldehyde semicarbazones and the application in controlling plant diseases |
CN104974053B (en) * | 2015-06-24 | 2017-04-26 | 天津久日新材料股份有限公司 | Novel aminoketones photoinitiator and application in UV-LED photocuring system |
Citations (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE639727A (en) | 1962-11-13 | |||
BE622079A (en) | 1961-09-11 | |||
BE667022A (en) | ||||
BE612755A (en) | 1961-01-19 | 1962-07-17 | Merck & Co Inc | (Alpha -alkylidene acyl) -phenyl compounds and their preparation |
US3139458A (en) | 1963-02-12 | 1964-06-30 | Upjohn Co | Semicarbazones of naphthaldehydes and 5h benzocycloheptene-8-carboxaldehydes |
US3251064A (en) | 1962-11-13 | 1966-05-10 | Everett M Schultz | beta-aminoacylphenoxy-and beta-aminoacylphenylmercapto-derivatives of monocarboxylicacids |
US3255241A (en) | 1961-01-19 | 1966-06-07 | Merck & Co Inc | (2-alkylidene acyl)phenoxy-and (2-alkylidene acyl)phenylmercaptocarboxylic acids |
US3300484A (en) | 1963-12-26 | 1967-01-24 | Searle & Co | Process and intermediates for manufacture of 13-alkyl-3, 17-bisoxygenated gona-1, 3, (10)-trienes |
US3303214A (en) | 1964-05-13 | 1967-02-07 | Wallace & Tiernan Inc | Nitrososemicarbazides |
US3304323A (en) | 1964-03-20 | 1967-02-14 | Upjohn Co | Oxygenated dicycloalkyl sulfones |
US3392171A (en) | 1964-03-20 | 1968-07-09 | Upjohn Co | 4-morpholino-4'-hydroxy bicyclohexyls |
US3558654A (en) | 1966-08-23 | 1971-01-26 | May & Baker Ltd | Semicarbazone and thiosemicarbazone quaternary salts |
US3712914A (en) | 1970-05-14 | 1973-01-23 | Stauffer Chemical Co | Arylidene semicarbizides |
US4015011A (en) | 1974-04-27 | 1977-03-29 | Boehringer Ingelheim Gmbh | Phenylalkylamines and salts thereof |
EP0065485A2 (en) | 1981-05-12 | 1982-11-24 | Ciba-Geigy Ag | Arylphenyl ether derivatives as microbicides, process for their preparation and their application |
US4394514A (en) | 1981-04-30 | 1983-07-19 | Smithkline Beckman Corporation | Processes for preparing 4-substituted indoles |
US4454337A (en) | 1981-06-29 | 1984-06-12 | Smithkline Beckman Corporation | Semicarbazide intermediates for preparing 4-substituted indoles |
US5236957A (en) | 1989-05-25 | 1993-08-17 | Farmitalia Carlo Erba Srl | N-phenylalkyl substituted α-amino carboxamide derivatives and process for their preparation |
US5266585A (en) | 1981-05-12 | 1993-11-30 | Ciba-Geigy Corporation | Arylphenyl ether derivatives, compositions containing these compounds and use thereof |
WO1994006758A1 (en) | 1992-09-21 | 1994-03-31 | University Of Saskatchewan | Aryl semicarbazone anticonvulsants |
WO1995031448A1 (en) | 1994-05-17 | 1995-11-23 | Dowelanco | N-(5-isothiazolyl)amide pesticides |
WO1996040628A1 (en) | 1995-06-07 | 1996-12-19 | The University Of Saskatchewan | Semicarbazones having cns activity and pharmaceutical preparations containing same |
WO1997016433A1 (en) | 1995-10-30 | 1997-05-09 | Smithkline Beecham Corporation | Protease inhibitors |
US5665673A (en) | 1988-12-29 | 1997-09-09 | Anderson; Richard J. | Potentiating herbicidal compositions |
-
1995
- 1995-06-07 US US08/475,313 patent/US5741818A/en not_active Ceased
-
1996
- 1996-06-07 RU RU98100258/04A patent/RU2174115C2/en not_active IP Right Cessation
- 1996-06-07 GE GEAP19964053A patent/GEP20012414B/en unknown
- 1996-06-07 ES ES96917304T patent/ES2164889T3/en not_active Expired - Lifetime
- 1996-06-07 CA CA002223935A patent/CA2223935A1/en not_active Abandoned
- 1996-06-07 BR BR9609408A patent/BR9609408A/en not_active Application Discontinuation
- 1996-06-07 PT PT96917304T patent/PT836591E/en unknown
- 1996-06-07 AU AU59938/96A patent/AU715897B2/en not_active Ceased
- 1996-06-07 HU HU9802637A patent/HUP9802637A3/en unknown
- 1996-06-07 DK DK96917304T patent/DK0836591T3/en active
- 1996-06-07 WO PCT/CA1996/000380 patent/WO1996040628A1/en not_active Application Discontinuation
- 1996-06-07 IL IL12235096A patent/IL122350A0/en unknown
- 1996-06-07 PL PL96323666A patent/PL184048B1/en unknown
- 1996-06-07 DE DE69615558T patent/DE69615558T2/en not_active Expired - Fee Related
- 1996-06-07 EP EP96917304A patent/EP0836591B1/en not_active Expired - Lifetime
- 1996-06-07 CZ CZ973874A patent/CZ387497A3/en unknown
- 1996-06-07 JP JP9500044A patent/JPH11506109A/en not_active Withdrawn
- 1996-06-07 CN CN96195385A patent/CN1062263C/en not_active Expired - Fee Related
- 1996-06-07 KR KR1019970708888A patent/KR19990022408A/en not_active Application Discontinuation
- 1996-06-07 AT AT96917304T patent/ATE206110T1/en not_active IP Right Cessation
- 1996-06-07 NZ NZ309707A patent/NZ309707A/en unknown
- 1996-07-06 UA UA98010024A patent/UA62915C2/en unknown
-
1997
- 1997-12-05 NO NO19975663A patent/NO310655B1/en not_active IP Right Cessation
- 1997-12-05 FI FI974447A patent/FI974447A0/en unknown
-
2000
- 2000-04-20 US US09/556,910 patent/USRE38425E1/en not_active Expired - Fee Related
Patent Citations (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE667022A (en) | ||||
BE612755A (en) | 1961-01-19 | 1962-07-17 | Merck & Co Inc | (Alpha -alkylidene acyl) -phenyl compounds and their preparation |
US3255241A (en) | 1961-01-19 | 1966-06-07 | Merck & Co Inc | (2-alkylidene acyl)phenoxy-and (2-alkylidene acyl)phenylmercaptocarboxylic acids |
US3213139A (en) | 1961-09-11 | 1965-10-19 | Hoffmann La Roche | Method for the preparation of 2-aminobenzophenones |
BE622079A (en) | 1961-09-11 | |||
US3251064A (en) | 1962-11-13 | 1966-05-10 | Everett M Schultz | beta-aminoacylphenoxy-and beta-aminoacylphenylmercapto-derivatives of monocarboxylicacids |
BE639727A (en) | 1962-11-13 | |||
US3324121A (en) | 1962-11-13 | 1967-06-06 | Merck & Co Inc | Alpha-(secondary aminomethyl)acylphenoxy (and phenylmercapto) monocarboxylic acids |
US3139458A (en) | 1963-02-12 | 1964-06-30 | Upjohn Co | Semicarbazones of naphthaldehydes and 5h benzocycloheptene-8-carboxaldehydes |
US3300484A (en) | 1963-12-26 | 1967-01-24 | Searle & Co | Process and intermediates for manufacture of 13-alkyl-3, 17-bisoxygenated gona-1, 3, (10)-trienes |
US3304323A (en) | 1964-03-20 | 1967-02-14 | Upjohn Co | Oxygenated dicycloalkyl sulfones |
US3392171A (en) | 1964-03-20 | 1968-07-09 | Upjohn Co | 4-morpholino-4'-hydroxy bicyclohexyls |
US3303214A (en) | 1964-05-13 | 1967-02-07 | Wallace & Tiernan Inc | Nitrososemicarbazides |
US3558654A (en) | 1966-08-23 | 1971-01-26 | May & Baker Ltd | Semicarbazone and thiosemicarbazone quaternary salts |
US3712914A (en) | 1970-05-14 | 1973-01-23 | Stauffer Chemical Co | Arylidene semicarbizides |
US4015011A (en) | 1974-04-27 | 1977-03-29 | Boehringer Ingelheim Gmbh | Phenylalkylamines and salts thereof |
US4394514A (en) | 1981-04-30 | 1983-07-19 | Smithkline Beckman Corporation | Processes for preparing 4-substituted indoles |
EP0065485A2 (en) | 1981-05-12 | 1982-11-24 | Ciba-Geigy Ag | Arylphenyl ether derivatives as microbicides, process for their preparation and their application |
US5266585A (en) | 1981-05-12 | 1993-11-30 | Ciba-Geigy Corporation | Arylphenyl ether derivatives, compositions containing these compounds and use thereof |
US4454337A (en) | 1981-06-29 | 1984-06-12 | Smithkline Beckman Corporation | Semicarbazide intermediates for preparing 4-substituted indoles |
US5665673A (en) | 1988-12-29 | 1997-09-09 | Anderson; Richard J. | Potentiating herbicidal compositions |
US5502079A (en) | 1989-05-25 | 1996-03-26 | Farmitalia Carlo Erba S.R.L. | N-phenylalkyl substituted α-amino carboxamide derivatives and process for their preparation |
US5391577A (en) | 1989-05-25 | 1995-02-21 | Farmitalia Carlo Erba S R L | N-phenylalkyl substituted α-amino carboxamide derivatives and process for their preparation |
US5236957A (en) | 1989-05-25 | 1993-08-17 | Farmitalia Carlo Erba Srl | N-phenylalkyl substituted α-amino carboxamide derivatives and process for their preparation |
WO1994006758A1 (en) | 1992-09-21 | 1994-03-31 | University Of Saskatchewan | Aryl semicarbazone anticonvulsants |
WO1995031448A1 (en) | 1994-05-17 | 1995-11-23 | Dowelanco | N-(5-isothiazolyl)amide pesticides |
WO1996040628A1 (en) | 1995-06-07 | 1996-12-19 | The University Of Saskatchewan | Semicarbazones having cns activity and pharmaceutical preparations containing same |
WO1997016433A1 (en) | 1995-10-30 | 1997-05-09 | Smithkline Beecham Corporation | Protease inhibitors |
US5998470A (en) | 1995-10-30 | 1999-12-07 | Smithkline Beecham Corporation | Protease inhibitors |
Non-Patent Citations (127)
Title |
---|
Abstract of Hungarian Patent No. 189136, published Apr. 28, 1984. |
Abstract of Hungarian Patent No. 214006, published Jun. 28, 1995. |
American Chemical Society, CAS file CAOLD, see Registry No. 101091-62-7, 1987. |
American Chemical Society, CAS file CAOLD, see Registry No. 107921-04-0, 1987. |
American Chemical Society, CAS file CAOLD, see Registry No. 114399-26-7, 1988. |
American Chemical Society, CAS file CAOLD, see Registry No. 115229-17-9, 1988. |
American Chemical Society, CAS file CAOLD, see Registry No. 1158-22-1, 1968. |
American Chemical Society, CAS file CAOLD, see Registry No. 92968-95-1, 1985. |
American Chemical Society, CAS file CAOLD, see Registry No. 93651-16-2, 1985. |
American Chemical Society, CAS file CAOLD, see Registry No. 93899-42-4, 1985. |
American Chemical Society, CAS file CAOLD, see Registry No. 94960-09-5, 1985. |
American Chemical Society, CAS file CAOLD, see Registry No. 95135-19-6, 1985. |
American Chemical Society, CAS file CAPLUS, see Registry No. 144141-11-7, 1993. |
American Chemical Society, CAS file CAPLUS, see Registry No. 174521-23-4, 1996. |
American Chemical Society, CAS file CAPLUS, see Registry No. 190657-77-3, 1998. |
American Chemical Society, CAS file CAPLUS, see Registry No. 22263-45-2, 1970. |
American Chemical Society, CAS file CAPLUS, see Registry No. 36934-63-1 and 36934-64-2, 1973. |
American Chemical Society, CAS file CAPLUS, see Registry No. 54291-81-5, 1975. |
Badische Anilin & Soda-Fabrik A.-G., "Terephthaldialdehyde," Chemical Abstracts 65, abstract 5405b, American Chemical Society (1966). See 5412e. |
Baltzly, R. et al., "2,4-Diamino-5-[4'-fluoro-3'-halogenophenyl]pyrimidines," J. Organic Chem. 26:2353-2355, American Chemical Society (1961). |
Baltzly, R. et al., "2,4-Diamino-5-[4′-fluoro-3′-halogenophenyl]pyrimidines," J. Organic Chem. 26:2353-2355, American Chemical Society (1961). |
Bayoumy, B. E.-S. and L. Skulski, "Synthesis of Some New Diaryl Sulphides and Diaryl Sulphones Containing 1,2,3-Thiadiazole Moiety," Bull. Pol. Acad. Sci. Chem. 39:455-458, Warsaw (1991). |
Beilstein Informationgesellschaft GmbH, see Belstein Registry No. 1890700, 1940. |
Beilstein Informationgesellschaft GmbH, see Belstein Registry No. 2541223, 1940. |
Beilstein Informationgesellschaft GmbH, see Belstein Registry No. 3178769, 1940. |
Beilstein Informationgesellschaft GmbH, see Belstein Registry No. 3347507, 1940. |
Beilstein Informationgesellschaft GmbH, see Belstein Registry No. 3382967, 1940. |
Beilstein Informationgesellschaft GmbH, see Belstein Registry No. 3389800, 1939. |
Beilstein Informationgesellschaft GmbH, see Belstein Registry No. 3396690, 1939. |
Beilstein Informationgesellschaft GmbH, see Belstein Registry No. 3400167, 1940. |
Beilstein Informationgesellschaft GmbH, see Belstein Registry No. 3400193, 1940. |
Beilstein Informationgesellschaft GmbH, See Belstein Registry No. 3410343, 1940. |
Beilstein Informationgesellschaft GmbH, see Belstein Registry No. 3417848, 1940. |
Beilstein Informationgesellschaft GmbH, see Belstein Registry No. 3419487, 1940. |
Beilstein Informationgesellschaft GmbH, see Belstein Registry No. 3421220, 1940. |
Beilstein Informationgesellschaft GmbH, see Belstein Registry No. 3422330, 1940. |
Beilstein Informationgesellschaft GmbH, see Belstein Registry No. 3436628, 1940. |
Beilstein Informationgesellschaft GmbH, see Belstein Registry No. 3449771, 1940. |
Beilstein Informationgesellschaft GmbH, see Belstein Registry No. 3468481, 1941. |
Beilstein Informationgesellschaft GmbH, see Belstein Registry No. 3468486, 1941. |
Beilstein Informationgesellschaft GmbH, see Belstein Registry No. 3508814, 1941. |
Beilstein Informationgesellschaft GmbH, see Belstein Registry No. 3532377, 1941. |
Beilstein Informationgesellschaft GmbH, see Belstein Registry No. 5349918, 1945. |
Chemical Abstract 50 4836 (1956). * |
Complaint, filed Jan. 2, 2002, Puthucode v. The University of Saskatchewan Technologies, Inc., United States District Court for the District of Columbia, case No. 1:02CV00001. |
Complaint, filed Sep. 24, 2001, Puthucode v. Godici, United States District Court for the Northern District of Texas, case No. 3:01CV1902-D. |
Defendant UST's Motion to Dismiss for Failure to Join Necessary and Indispensable Parties, dated Feb. 19, 2002, Puthucode v. The University of Saskatchewan Technologies, Inc., United States District Court for the District of Columbia, case No. 1:02CV00001. |
Defendant's Motion to Dismiss (with prejudice), filed Nov. 21, 2001, Puthucode v. Godici, United States District Court for the Northern District of Texas, case No. 01-CV-1902-D. |
Demetresco, C. et al., "p-Alkoxyphenyl p-substituted-phenyl sulfone series. III. Derivatives with potential pharmacodynamic action," Chemical Abstracts 70, abstract 106164s, American Chemical Society (1969). |
Demetresco, C. et al., "p-Alkoxyphenyl p-substituted-phenyl sulfone series. III. Derivatives with potential pharmacodynamic action," Chim. Ther. 3:343-347, Societe Francaise de Chimie Therapeutique; Editions Scientifiques et Medicale Elsevier (1968). [In French]. |
Dimmock, J.R. et al., "(Aryloxy)aryl Semicarbazones and Related Compounds: A Novel Class of Anticonvulsant Agents Possessing High Activity in the Maximal Electroshock Screen," Journal of Medicinal Chemistry 39:3984-3997, American Chemical Society (1996). |
Dimmock, J.R. et al., "Anticonvulsant Activities of Some Arylsemicarbazones Displaying Potent Oral Activity in the Maximal Electroshock Screen in Rats Accompanied by High Protection Indices," J. Med. Chem 36:2243-2252, American Chemical Society (1993). |
Dimmock, J.R. et al., "Evaluation of acrylophenones and related bis-Mannich bases against murine P388 leukemia," European Journal of Medicinal Chemistry 22:545-551, Elsevier (1987). |
Dimmock, J.R. et al., "Evaluation of some Mannich bases of 1-aryl-1-ethanones and related ketones for anticonvulsant activities," Pharmazie 46:538-539, Verlag Gesundheit GmbH (1991). |
Dimmock, J.R. et al., "Evaulation of the thiosemicarbazones of some aryl alkyl ketones and related compounds for anticonvulsant activities," Eur. J. Med. Chem. 26:529-534, Elsevier (1991). |
Dimmock, J.R. et al., "Some aryl semicarbazones possessing anticonvulsant activities," Eur. J. Med. Chem. 30:287-301, Elsevier (1995). |
Dimmock, J.R. et al., "Structural modifications of the primary amino group of anticonvulsant aryl semicarbazones," Pharmazie 51:83-88, Govi-Verlag Pharmazeutischer Verlag GmbH Eschborn (1996). |
English language translation of Horii, Z. and T. Kinouchi, "On Hydrazones, which are Derived from p-Thiocyanatophenylhydrazine (Part IV)," Yakugaku Zasshi (J. Pharm. Soc. Japan) 57:123-124, Nippon Yakugakkai (1937). |
English language translation of Ito, G., "Synthesis of Guanidine Compounds of Diphenyl Ether II. A New Synthesis of Diphenyl Ether Aldehyde According to Sommelet and Experiments with Methylguanidine Derivatives (1).," Pharm. Bull (Tokyo) 5:401-405, Pharmaceutical Society of Japan (1957). |
English language translation of Ito, G., "Synthesis of Guanidine Compounds of Diphenyl Ethers. I.," Pharm. Bull. (Tokyo) 5:397-400, Pharmaceutical Society of Japan (1957). |
English language translation of Julia, M.M. and M. Baillarge, "Plant Growth Factors. IV. Some Substituted p-Phenoxy-phenylacetic Acids," Bull. Soc. Chim. Fr., Fifth Series. 20:644-647, Masson et Cie (1953). |
English language translation of Kimoto, S. et al., "Studies on the Friedel-Crafts Reaction of Diphenyl Ether Derivatives. III.," Yakugaku Zasshi (J. Pharm. Soc. Japan) 73:243-244, Pharmaceutical Society of Japan (1953). |
English language translation of Kimoto, S. et al., "Studies on The Friedel-Crafts Reaction of Diphenyl Ether Derivatives. VI. Reaction of Monochlorodiphenyl Ether and Acetyl Chloride," Yakugaku Zasshi (J. Pharm. Soc. Japan) 74:358-360, Pharmaceutical Society of Japan (1954). |
English language translation of Kimoto, S. et al., "Syntheses of Allied Compounds of Chloramphenicol I.," Yakugaku Zasshi (J. Pharm. Soc. Japan) 72:496-497, Pharmaceutical Society of Japan (1952). |
English language translation of Kimoto. S. and K. Asaki, "Studies on the Friedel-Crafts Reaction in Diphenyl Ether Derivatives. Part II.," Yakugaku Zasshi (J. Pharm. Soc. Japan) 72:300-303, Pharmaceutical Society of Japan (1952). |
English language translation of Tomita, M. et al., "Synthesis of Aldehyde Derivatives Containing a Diphenyl Ether Unit," Yakugaku Zasshi (J. Pharm. Soc. Japan) 75:1021-1023, Pharmaceutical Society of Japan (1955). |
Facsimile letter dated Apr. 20, 2001, from Branko F. Peterman (President & CEO, University of Saskatchewan Technologies Inc.) to Charles E. Phipps (Locke Liddell & Sapp LLP) enclosing a facsimile letter dated Apr. 19, 2001, from Norris M. Eades (Kirby, Eades, Gale, Baker) to Bin Yan (University of Sadkatchewan Technologies Inc.). |
Facsimile letter dated Apr. 9, 2001, from Branko F. Peterman (President & CEO, University of Saskatchewan Technologies Inc.) to Charles E. Phipps (Locke Liddell & Sapp LLP). |
Facsimile letter dated Aug. 8, 2001, from Charles E. Phipps (Locke Liddell & Sapp LLP) to Bin Yan (University of Saskatchewan Technologies Inc.) enclosing "a copy of a Complaint". |
Facsimile letter dated Mar. 30, 2001, from Charles E. Phipps (Locke Liddell & Sapp LLP) to Howard R. Udell (Executive Vice President and General Counsel, Purdue Pharma L.P.) and Bob Sadler (University of Saskatchewan Technologies Inc.). |
Facsimile letter dated May 3, 2001, from Charles E. Phipps (Locke Liddell & Sapp LLP) to Branko F. Peterman (President & CEO, University of Saskatchewan Technologies Inc.). |
Faltis,F. et al., "Biscoclaurine Alkaloids. Constitution of Chondodendrine and Trilobine," Chem. Ber. 74:79-97, Verlag Chemie GmbH (1941). [In German]. |
Faltis,F. et al., "Bisoclaurine Alkaloids. Constitution of Chondodendrine and Trilobine," Chemical Abstracts 35, abstract 5121f, American Chemical Society (1941). |
Fujikawa, F. et al., "Syntheses of Depsidones. I.," Chemical Abstracts 60, abstract 10685d, American Chemical Society (1964). |
Fujikawa, F. et al., "Syntheses of Depsidones. I.," Yakugaku Zasshi (J. Pharm. Soc. Japan) 63:1172-1174, Pharmaceutical Society of Japan (1963). [In Japanese]. |
Gorbacheva, I.N. et al., "Synthesis of Substituted Diphenyl Ethers," Journal of General Chemistry of the USSR 25:2259-2263, Consultants Bureau, Inc. (1955). |
Harington, C.R. and R.V. Pitt Rivers, "A New Synthesis of Thyronine," J. Chem. Soc. 1101-1103, The Chemical Society (1940). |
Harington, C.R., "Chemistry of Thyroxine. II. Constitution and Synthesis of Desiodo-Thyroxine," Biochem. J. 20:300-313, London Portland Press (1926). |
Horii, Z. and T. Kinouchi, "On Hydrazones, which are Derived from p-Thiocyanatophenylhydrazine (Part IV)," Yakugaku Zasshi (J. Pharm. Soc. Japan) 57:123-124, Nippon Yakugakkai (1937). [In German]. |
Ingersoll, A.W. et al., "Extensions of the Leuckart Synthesis of Amines," J. Am. Chem. Soc. 58:1808-1811, Mack Printing Co. (1936). |
International Search Report of International Application No. PCT/CA96/00380, filed Jun. 7, 1996. |
Ito, G., "Synthesis of Guanidine Compounds of Diphenyl Ether II. A New Synthesis of Diphenyl Ether Aldehyde According to Sommelet and Experiments with Methylguanidine Derivatives (1).," Pharm. Bull. (Tokyo) 5:401-403, Pharmaceutical Society of Japan (1957). [In German]. |
Ito, G., "Synthesis of Guanidine Compounds of Diphenyl Ethers. I.," Pharm. Bull. (Tokyo) 5:397-400, Pharmaceutical Society of Japan (1957). [In German]. |
J.R. Dimmock, Notes for Weekly Meetings with Puthucode, from Feb. 12, 1993 to Mar. 8, 1996. |
J.R. Dimmock, Project Notes: Sep. 3, 1993; Sep. 8, 1993; Aug. 31, 1993; Mar. 24, 1994; Mar. 25, 1994; Mar. 19, 1994; Jan. 6, 1995 and an undated project note. |
Julia, M.M. and M. Baillarge, "Plant Growth Factors. IV. Some Substituted p-Phenoxy-phenylacetic Acids," Bull. Soc. Chim. Fr., Fifth Series, 20:644-647, Massson et cie (1953). [In French]. |
Kimoto, S. et al., "Syntheses of Allied Compounds of Chloramphenicol I.," Yakugaku Zasshi (J. Pharm. Soc. Japan) 72:496-497, Pharmaceutical Society of Japan (1952). [In Japanese]. |
Kimoto, S. et al., "Studies on the Friedel-Crafts Reaction of Diphenyl Ether Derivatives, III.," Yakugaku Zasshi (J. Pharm. Soc. Japan) 73:243-244, Pharmaceutical Society of Japan (1953). [In Japanese]. |
Kimoto, S. et al., "Studies on the Friedel-Crafts Reaction of Diphenyl Ether Derivatives. VI. Reaction of Monochlorodiphenyl Ether and Acetyl Chloride," Yakugaku Zasshi (J. Pharm. Soc. Japan) 74:358-360, Pharmaceutical Society of Japan (1954). [In Japanese]. |
Kimoto. S. and K. Asaki, "Studies on the Friedel-Crafts Reaction in Diphenyl Ether Derivatives. Part II.," Yakugaku Zasshi (J. Pharm. Soc. Japan) 72:300-303, Pharmaceutical Society of Japan (1952). [In Japanese]. |
Krall, R.L. et al., "Antiepileptic Drug Development: II. Anticonvulsant Drug Screening," Epilepsia 19:409-428, Raven Press (1978). |
Memorandum dated Apr. 19, 1995, from J.R. Dimmock to Mr. B. Sadler (University of Saskatchewan Technologies Inc.), copied to RNP [R.N. Puthucode]. |
Memorandum dated Jun. 9, 1997, from J.R. Dimmock to "To Whom It May Concern". |
Memorandum dated Oct. 4, 1995 from J.R. Dimmock to "To Whom It May Concern". |
Memorandum from J.R. Dimmock to R.N. Puthucode dated Dec. 29, 1992. |
Memorandum from J.R. Dimmock to R.N. Puthucode dated Jul. 26, 1994. |
Memorandum from J.R. Dimmock to R.N. Puthucode dated Jun. 7, 1993. |
Memorandum from J.R. Dimmock to R.N. Puthucode dated Mar. 28, 1995. |
Memorandum from J.R. Dimmock to R.N. Puthucode dated Mar. 30, 1994. |
Memorandum from J.R. Dimmock to R.N. Puthucode dated Nov. 16, 1993. |
Memorandum Opinion and Order, dated Mar. 28, 2002, Puthucode v. The University of Saskatchewan Technologies, Inc., United States District Court for the District of Columbia, case No. 1:02CV00001. |
Nerurkar, J.J. et al., β-Arylglutaconic acids. IV. Synthesis of crotono- and valerolactones of β-arylglutaconic and glutaric acids. J. Org. Chem. 25:1491-1495, American Chemical Society (1960). |
Notice of Voluntary Dismissal, filed Nov. 30, 2001, Puthucode v. Godici, United States District Court for the Northern District of Texas, case No. 3-01CV1902-D. |
Novelty Search Report of Hungarian Patent Application No. P98 02637, completed Aug. 23, 2000. |
Ochiai, E. and Y. Tamai, "Friedel-Crafts Reaction of Diphenyl Ethers with Succinic Acid Chloride," Chemical Abstracts 59, abstract 7414b, American Chemical Society (1963). |
Ochiai, E. and Y. Tamai, "Friedel-Crafts Reaction of Diphenyl Ethers with Succinic Acid Chloride," Itsuu Kenkyusho Nempo, No. 12:39-41, Research Foundation Itsuu Laboratory (1962). [In German]. |
Order, filed Nov. 30, 2001, Puthucode v. Godici, United States District Court for the Northern District of Texas, case No. 3:01-CV-1902-D. |
Puthucode, N.R., "Synthesis and Anticonvulsant Evaluation of Some Aryl Semicarbazones," Report No. 2 (Sep. 1995). |
Puthucode, R.N., "Design and Synthesis of Some Aryloxyaryl Semicarbazones and Related Compounds as Novel Anticonvulsants," Ph.D. Thesis, The University of Saskatchewan, Canada, 202 pp., UMI Dissertation Services (Spring 1996). |
Racine, R.J., "Modification of Seizure Activity by Electrical Stimulation: II. Motor Seizure," Electroenceph. Clin. Neurophysiol. 32:281-294, Elsevier Publishing Co. (1972). |
Ramanan, P.N., Laboratory Notebook, May 8, 1995 to Mar. 21, 1996. |
Ramanan, P.N., N.B. #3, Feb. 7, 1994 to May 4, 1995. |
Rubinchik, M.A. and O.N. Tolkachev, "Study of the antiprotozoal activity of compounds of a group of diphenyl ethers and some nitrostyrenes," Med. Parazitol. Parazit. Bolezni 45:531-536, Izd-Vo "Meditsina" (1976). [In Russian]. |
Rubinichik, M.A. and O.N. Tolkachev, "Study of the antiprotozoal activity of compounds of a group of diphenyl ethers and some nitrostyrenes," Chemical Abstracts 86, abstract 115615x, American Chemical Society (1977). |
Samaritoni, J.G. et al., "Methylene Group Modifications of the N-(Isothiazol-5-yl)phenylacetamides. Synthesis and Insecticidal Activity," J. Agric. Food Chem. 47:3381-3388, American Chemical Society (Aug. 1999). |
Skeen, G. et al., "Development of Kindled Seizures Following Electrical Stimulation via the Cornea," Soc. Neurosci. Abstracts 16:307, Abstract No. 138.1, Society for Neuroscience (1990). |
Tomimatsu, T. and Y. Kano, "Alkaloids of Thalictrum thunbergii. XIII. Structure of thalicberine and O-methylthalicberine. 5.," Chemical Abstracts 59, abstract 3971b, American Chemical Society (1963). |
Tomimatsu, T. and Y. Kano, "Alkaloids of Thalictrum thunbergii. XIII. Structure of thalicberine and O-methylthalicberine. 5.," Yakugaku Zasshi (J. Pharm. Soc. Japan) 83:153-158, Pharmaceutical Society of Japan (1963). [In Japanese]. |
Tomita, M. et al., "Synthesis of Aldehyde Derivatives Containing a Diphenyl Ether Unit," Yakugaku Zasshi (J. Pharm. Soc. Japan) 75:1021-1023, Pharmaceutical Society of Japan (1955). [In Japanese]. |
Trust, R.I. et al., "(Aryloxy) [p- (aryloxy)phenyl]- and (Aryloxy) [p- (arylthio)phenyl]acetic Acids and Esters as Hypolipidemic Agents," Journal of Medicinal Chemistry 22:1068-1074, American Chemical Society (1979). |
Ungnade, H.E. and E.F. Orwoll, "The Gattermann Reaction in the Mono-methoxydiphenyl Ethers," J. Am. Chem. Soc. 65:1736-1738, Mack Printing Co. (1943). |
Vichkanova, S.A. et al., "Structure and antituberculous activity of some diphenyl ethers," Chemical Abstracts 82, abstract 106878a, American Chemical Society (1975). |
Vichkanova, S.A. et al., "Structure and antituberculous activity of some diphenyl ethers," Farmakol. Toksikol. (Moscow) 37:711-715, Gosudarstrennoe izd-vomeditsinskoi literatur (1974). [In Russian]. |
Volynskaya, E.M. et al., "Monophosphonium salts and monophosphoranes based on 4,4′-diacetylbiphenyl and its derivatives," Chemical Abstracts 77, abstract 101775b, American Chemical Society (1972). |
Volynskaya, E.M. et al., "Monophosphonium salts and monophosphoranes based on 4,4′-diacetylbiphenyl and its derivatives," Zh. Obshch. Khim. 42:986-992, Maik Nauka (1972). [In Russian]. |
Walker, J., "Experiments on the Synthesis of Potential Cortical Hormone Substitutes. Hydroxycarbonyl Derivatives of Diphenyl Ether and Related Compounds," J. Chem. Soc. 347-353, The Chemical Society (1942). |
Yeager, G.W. and D.N. Schissel, "A Convenient Method for the Preparation of 4-Aryloxyphenols," Synthesis (1):63-68, Georg Thieme Verlag Stuttgart, Thieme Medical Publishers, Inc. (1991). |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7074813B2 (en) | 2001-05-10 | 2006-07-11 | Cytovia, Inc. | Substituted N′-(arylcarbonyl)-benzhydrazides, N′-(arylcarbonyl)-benzylidene-hydrazides and analogs as activators of caspases and inducers of apoptosis and the use thereof |
US20090186893A1 (en) * | 2007-06-08 | 2009-07-23 | Mannkind Corporation | IRE-1alpha INHIBITORS |
US7858666B2 (en) | 2007-06-08 | 2010-12-28 | Mannkind Corporation | IRE-1α inhibitors |
US20110065162A1 (en) * | 2007-06-08 | 2011-03-17 | Mannkind Corporation | IRE-1alpha INHIBITORS |
US8614253B2 (en) | 2007-06-08 | 2013-12-24 | Mannkind Corporation | IRE-1α inhibitors |
US9241942B2 (en) | 2007-06-08 | 2016-01-26 | Mannkind Corporation | IRE-1α inhibitors |
US9546149B2 (en) | 2007-06-08 | 2017-01-17 | Mannkind Corporation | IRE-1α inhibitors |
US9981901B2 (en) | 2007-06-08 | 2018-05-29 | Fosun Orinove Pharmatech, Inc. | IRE-1α inhibitors |
Also Published As
Publication number | Publication date |
---|---|
DE69615558T2 (en) | 2002-07-11 |
HUP9802637A2 (en) | 1999-02-01 |
DE69615558D1 (en) | 2001-10-31 |
FI974447A (en) | 1997-12-05 |
DK0836591T3 (en) | 2001-11-26 |
WO1996040628A1 (en) | 1996-12-19 |
UA62915C2 (en) | 2004-01-15 |
CZ387497A3 (en) | 1998-07-15 |
NZ309707A (en) | 1998-11-25 |
CN1190388A (en) | 1998-08-12 |
ATE206110T1 (en) | 2001-10-15 |
PL184048B1 (en) | 2002-08-30 |
JPH11506109A (en) | 1999-06-02 |
EP0836591B1 (en) | 2001-09-26 |
KR19990022408A (en) | 1999-03-25 |
IL122350A0 (en) | 1998-04-05 |
AU715897B2 (en) | 2000-02-10 |
ES2164889T3 (en) | 2002-03-01 |
RU2174115C2 (en) | 2001-09-27 |
FI974447A0 (en) | 1997-12-05 |
EP0836591A1 (en) | 1998-04-22 |
GEP20012414B (en) | 2001-04-25 |
AU5993896A (en) | 1996-12-30 |
NO975663D0 (en) | 1997-12-05 |
NO975663L (en) | 1998-02-09 |
HUP9802637A3 (en) | 2000-09-28 |
BR9609408A (en) | 1999-07-27 |
US5741818A (en) | 1998-04-21 |
NO310655B1 (en) | 2001-08-06 |
PL323666A1 (en) | 1998-04-14 |
CN1062263C (en) | 2001-02-21 |
CA2223935A1 (en) | 1996-12-19 |
PT836591E (en) | 2002-03-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
USRE38425E1 (en) | Semicarbazones having CNS activity and pharmaceutical preparations containing same | |
EP0582630B1 (en) | N6 -(hydrazinoiminomethyl)lysine and method of inhibiting nitric oxide formation in body | |
JPH06256291A (en) | Substituted benzoylguanidine and preparation thereof | |
IE48368B1 (en) | Imidazole derivatives | |
JP2588977B2 (en) | Benzene derivatives, their preparation and pharmaceutical compositions containing them | |
Shiozawa et al. | Synthesis and activity of 2-methyl-3-aminopropiophenones as centrally acting muscle relaxants | |
US6706895B1 (en) | 4-methoxybiphenyl hydrazone derivatives | |
Basil et al. | New class of sympathetic. beta.-receptor blocking agents. 3, 4-Dihydro-3-hydroxy-1, 5-benzoxazocines | |
BR112020014237A2 (en) | ALDH2 ACTIVATOR | |
US6482982B1 (en) | Halogenated antituberculosis agents | |
GB2053897A (en) | Piperazine derivatives | |
EP0380355A2 (en) | Carbamates of 6-chloro-7,8-dihydroxy-1-(4'-Hydroxyphenyl)-2,3,4,5-tetra-hydro-1H-3-benzazepine as prodrugs | |
SU900808A3 (en) | Process for preparing aminopropanol derivatives of 6-hydroxy-2,3,4,5-tetrahydro-1h-1-benzaszepine-2-one or their salts | |
MXPA97009311A (en) | Semicarbazonas that have activity in the central sistemanervioso and pharmaceutical preparations that contain them | |
CA1269107A (en) | Process for preparing new hydroxy alkoxy 4- phenylpropylindole derivatives and the salts thereof | |
CA1183872A (en) | Benzamido-alkyl-hydroxamic acid derivatives | |
US7432401B2 (en) | Method for the preparation of 1,5-bis(4-hydroxy-3-metoxy-phenyl)-penta-1,4-dien-3-one and derivatives with antitumoral properties | |
KR950004043B1 (en) | 2-(1-alkylaminoalkyl)-3-hydroxy-1,4-naphthoquinoue, process for its production and process for producing 2-(1-alkenyl)-3-2-alkyl-3-acylaxy-1,4-naphthoquinone by using it | |
US6930205B2 (en) | Process for preparing aminostilbene derivatives | |
GB2155014A (en) | Aminodiaryl sulfoxide derivatives | |
AU575132B2 (en) | Preperation of amidinoureas | |
GB2279345A (en) | Cyclohexanecarboxylic acid derivatives | |
JP2599964B2 (en) | Carbamate derivatives and herbicides containing the same as an active ingredient | |
JP3367057B2 (en) | Process for producing 4-tert-butyldioxy-2,5-cyclohexadien-1-ones | |
CA1042444A (en) | Preparation of tetrahydrocarbazoles |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: UNIVERSITY OF SASKATCHEWAN TECHNOLOGIES, INC., CAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SASKATCHEWAN, UNIVERSITY OF;REEL/FRAME:011575/0016 Effective date: 19970515 |
|
AS | Assignment |
Owner name: UNIVERSITY OF SASKATCHEWAN TECHNOLOGIES, INC., CAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:PUTHUCODE, RAMANAN NARAYAN;REEL/FRAME:012851/0873 Effective date: 19970515 |
|
REMI | Maintenance fee reminder mailed | ||
LAPS | Lapse for failure to pay maintenance fees |